Sham-operated animals
policy
taxonomy






Heart failure ; uk
CHF
air pollution ; heart failure
avantages ; cardiovascular system


hz
EH


diuretic ; heart failure


complications
cell ; Anand
doxorubicin
blood transfusions
Heart failure ; bisphosphonates

expression ; heart failure
right heart failure ; pulmonary hypertension

exercise ; cardiovascular health
surgery ; heart transplant recipients
hospital mortalité
Renal artery stenosis

hz ; pna
molecular
tertiary referral centre
EC

Liver
dXA
FM
heart failure




heart failure ; Latin America
HF


breathing ; heart

Heart


doctors
Nutrition ; heart failure
nordwest United States



heart failure


Heart

clin

trans


Internal reliability ; cronbach
hypertension


cox regression
implanted monitoring devices

conditions
hz ; burden

frailty ; heart failure

heart failure
RAS ; atherosclerosis
MicroRNAs ; heart failure ; disease management
PSSS
heart failure ; ejection fraction
Cardiology ; Bromodomain inhibition ; heart failure

heart failure ; cardiovascular death
cognitive function
co
vasopressin ; congestive heart failure
Mitral stenosis ; heart failure
cardiac transplantation
inpatient medical conditions
frailty ;HF

LV ; fibrosis ;ANS ; mice

dodson

CHF
heart failure
intermediate frailty
competitive ; collateral growth

autonomic balance
HFpEF
Jehovahs Witness ; anemia
ST2
Heart failure ; cognitive impairment ; mortalité
Department de cardiology ; university hospital

courant ;HF ;HF



Heart failure
hz ; MI

Remote ischemic conditioning ; heart failure
Heart ; cardiac
cardiovascular disease
rhythmia-related costs

pde2 ; hz
mortalité ; sts ; hm
physician ; hospital
Medication ; sST2
Heart failure ; public health
albumin

well-being

reliability ;HF
hospital ; coprimary outcome
ete ; CHF
eRK ; molecular scaffolds ; heart
spironolactone ; systolic heart failure

Heart failure ; hz ; mortalité
heart failure ; bisoprolol
Functional MS ; degenerative MR

VET ; aortic pressure curve
Cardiac ; lesions
Devices ; heart failure ;HF ; therapy
Trastuzumab-related cardiotoxicity ; breast cancer
physician continuity ; discharge
readmission
Tolvaptan ; vasopressin
readmission

propensity


etiology ; MR ; ms
Cardiac amyloidosis
ejection ; fraction ; sex ; bNP
HFpEF
beta blockade

Robot-assisted training ; heart failure

Chronic HF

Pigs ; antiarrhythmic medication
Heart ; arterial pressure
hz ; HRQol
ejection fraction ; trial
mortalité
cardiac ; inflammatory biomarkers
hz ; cardiovascular
CHF
hypothermic circulatory arrest
biomarkers ; heart failure
heart failure
systolic dysfunction
hz
nord America
acute heart failure

therapy
AHA ; ESC
cPGs
circulation
ms ; surgery
toxicité ; systemic blood pressure
patients ; heart failure
stand-alone diagnostic devices ; hz
heart failure
HF


multiorgan failure ; sepsis
Nordic walking ; heart failure
Self-Care ; Heart Failure
heart failure
acute kidney injury
cox
endothelial
heart failure ; cox
ms ; surgery ; echocardiography
pharmacologique ; acute heart failure
avantages
abnormal cardiac

heart failure
US ; healthcare
biomarkers
AIN oUTCOME ; tue



drug ; japon

VO2
life expectancy
Coronary angiography
dialysis ; implantation
off-pump ; sparing ; HeartMate II exchange
Hemodynamic ; Fontan
ESRD
Seattle ; Heart Failure Model

HR ;HF
Heart failure ; left ventricular ejection ;fraction
new-onset ; AI ; surgical
acute heart failure
ingenuity
Treatment ; lVAD
nursing ; nursing care

avantages ; anemia ; heart disease

QRs ; benefit

Rhythm ; rate-control

public ; hospitals
sinus rhythm ; af
septal ; filling pressures
management ; telehealth ; medicare


physicians ;HF
heart failure ; cardiac rehabilitation
Race ; spironolactone ; heart failure
Myocardial infarction ; Wistar rats

hz ; chromatin hyperacetylation
mortalité
grs ; CV ; af
ms ; surgery

medication ; hemodynamics
AIN
pathophysiological origin
systolic ;HF
postsystolic
lVAD ; implantation
Readmission ; hospital ; heart failure
gross income ; expenditure ; health

Mice ; ac ; cardiac hypertrophy
physique ; heart failure
skeletal muscle abnormalités ; exercise ; Fontan circulation
hypertension ; kidney failure
chronic kidney disease ; cd
hospital ; change
anaerobic ; heart failure
Mitral regurgitation ;HF
CHF ; unilateral renal ; DNx ; cardiac autonomic balance
renin-angiotensin-aldosterone system ; heart failure
HR ; cardiac death
resistin ; inflammation ; metabolism ; heart
Heart block ; pulmonary artery snared ; BiVP
management ; congenital heart lesions
surgical ; ms
echocardiographic examination
bioinformatic ; microarray ; heart failure
cardiovascular events
diuretic ; hz
CAD ; systolic ;HF
PVf ; recovery ; pb
Nurses
diabetes ;EO-cFUs
Blacks ; VO2
hospital clustering
change ; lVET
nitroxyl ; hno ; heart failure
physician continuity ; readmission ; discharge ; heart failure
hf ; HFpEF

hospital-to-Home ; hospital ; readmission reduction ; congestive heart failure
économique savings ; coût
hz
ct ; dialysis-dependent
ms ; hz ; ms

ICU ; mortalité
Cardiac ; pressure-volume ; catheter system
RM
beta-blockers
CHF
st2 ; benefit ; BB
idiopathic ; cardiomyopathy
Hypoalbuminemia ; heart failure
hypertensive LV ; MR ; ms
cd ; hz
angiotensin receptor ; inhibitor ; heart failure
Western blot ; immunohistochemistry ; electron microscopy
diastolic dysfunction ; peripheral artery disease
unfolded protein ; cardiac sodium current ; heart failure
ischemic cardiomyopathy ; mortalité
Exercise intolerance ; heart failure
biological phenotype ; mortalité
ete ; endothelial function
CV ; death ; stroke ; heart failure
avd ; VVD ; co ; réseau
Fat ; cachexia ; ventricle ; heart failure ; complicity
atrial fibrillation ; af ; heart failure
ECCT ; advanced heart failure ; therapy
heart transplantation ; left ventricular assist device
coronary disease ; heart failure
complications ; dialysis
ventricular ; body composition ; heart failure
eCGs ; electrocardiographers
ventricular assist device ; ventricular support
ESRD ; outpatients ; hz
Wilcoxon ; signed-rank
subclinical atherosclerosis
resistin ; heart failure
fréquence ; FM ; body weight ; CC
Renal artery stenosis ;RAS ; peripheral arterial disease
neurological ; cardiovascular
cardiac remodelling
proteome ; HDl
heart rate
social support ; exercise ; exercise
rehospitalization
Cardiac cachexia ;cc ; changes
ms ; surgery ; mva
proteins ;TAC
Mediterranean ; DASh ; food-frequency questionnaires
multihospital ; heart failure ; nurse
Frailty ;HF
Southeastern Minnesota ; hf
electrical activation
hHF ; dp-4 inhibiteurs ; drugs
af ; hf
heart transplant ; ECCT
cRF
hospitalisation ; heart failure
Cardiac-resynchronization ; heart failure ; QRs
medications ; heart failure
miRNAs ; cardiac
heart failure
bt ; dt ; implantation
mortalité
coronary heart disease ; stroke ; heart failure
mlf
lesions ; septal defects
mortalité ; iCD-HF
hz
hypotension
mortalité
β-blocker ;BB ; sST2
discharge ; follow-up

extubated ; blood loss ; transfusion
technique ; malfunctioning HeartMate ; lVADs
Heart failure ;HF ; cardiovascular
ST2
VEGF ; cardiac function ; remodeling
biomarkers ;HF
trastuzumab-related CHF
Healthy ; aerobic exercise
hospitals

transplants

Peak VO2
hospitals
pharmaceutically
bromodomain proteins
condition ; économique
financiers
preoperative hypoalbuminemia ; lVAD
holosystolic murmur ; heart
psoriasis ; atherosclerosis ; cardiovascular events ; Rotterdam
Coronary artery disease ;cad ; systolic heart failure ; hz
mortalité ;HF ; hospital admissions ; transplant ; ventricular assist device
Heart failure ; rheumatoid arthritis ; tNF
remodelling ; hf ; haemodynamic ; neuronal stressors
lVAD ; implantation
renal dysfunction ; transplant morbidité
ht ; germline DNA
Heart failure ; management ; medical
Renal DNx ; plasma ; CHF-inv ; rabbits

trastuzumab
NP ; ed
Cardiac hypertrophy ; energy metabolism
hz
blood work ; medication
st2 ; heart failure
Heart ; heart failure ; arrhythmias
Caspase ; paced myocardium
heart failure ; aging ; body composition
hf ; saxagliptin ; sitagliptin
hz
aCR ; CMS
HDl-bound malondialdehyde ; HDl-induced ; EC
ed ; intubations ; congestive heart failure
CAD ; CAD


hospital discharge
hospitals
avantages ; anemia ; heart disease
heart failure ; medication
expression ; regulatory subunit ;RI ; hz
heart failure ; ejection fraction
cPET ; rehabilitation ; CHF
nfat ; mir-25 ; transcription factor ; Hand2 ; heart failure
Pediatric ; heart failure ; hz
eplerenone
renal denervation ; autonomic balance ; rabbits ; heart failure
readmissions ; heart failure ; readmission quality improvement
resistin ; ejection fraction
Right atrial myxoma ; pulmonary embolisme ; vent failure
Orthotopic heart transplantation ; ot ; end-stage heart failure
Myxomas ; right atrium ; pulmonary arterial vasculature
ECCT ; cardiac transplant recipients
SD
vegetables ; nuts ; mortalité
benefit

iron
ed ; CHF
ventricular contractile ; pulmonary hypertension
Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
Soluble ST2 ; heart failure
echocardiograms ; reverse remodeling
Titin hypophosphorylation ; myocardial ;DD
hospital discharge ; heart failure
bottleneck ; stent ; chronic myocardial ischemia ; heart failure ; pigs
QT ; SD ; QT ;SD
LV ; filling pressure ; hz
MedLine ; eEMBAse ; cINAHL
benefit ;RAS ;blocker ; HFpEF
cPCs ; functional capacity ; VO2
pump ; driveline injury ; pump replacement
ischemic ; inflammatory abdominal problems ; MT
EH ;HFpEF
Framingham Heart Study ; hz ; EF
Nicorandil ; doxorubicin
therapies ; fees
acp ; clinical practice
diuretics ; congestive symptoms ; heart failure ; hz
canine ; heart failure ; tachycardia
lVAS ; bridge to transplantation ; therapy
Cardiac ; expression ; Mammalian ;Mena ; heart failure ; mice
eas ; rhythm control therapy ; cardiovascular complications ; af
hz
coronary artery disease ;cad
NOc ; admission to discharge
HRQol ; hgb
skeletal ; muscle mass ; VO2
atrial fibrillation ; pacemaker
inpatient ;HF
active
cardiac resynchronization ; dialysis-dependent ; heart failure
pneumonia ; conditions
diastolic failure ; cardiomyopathic
injections
pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis
emergency cardiac catheterization ; extubated
Psychosocial factors ; heart failure ; hz
medical management ; heart failure ; children ; Canadian Cardiovascular Society
ventricular-arterial coupling ; SV
benefit ; QRs ; ms
autonomic nervous system activity ; QTV
implantation ; ct
aRIC HF

change
degs ; osprey ; réseaus

World Health Organization ; hz ; la
Medicare ; post-acute care transfer ; policy
cardiovascular
paediatric cardiac transplants
AF-free ; catheter ablation ; sinus rhythm
body mass ; cRF ; treadmill exercise
myocardial tissue ; pKA
mortalité ; iCD-HF
mapping ; technique ; myocardial fibrosis

Medicare ; fee-for-service beneficiaries


SD ;SD

ethics Rounds

heart failure
ed ; visits ; CHF ; intubation
bisoprolol ; mortalité
Health Buddy Program ; content-driven telehealth system ; care management
muscle-wasting syndrome ; heart failure ; Fontan
Frailty ; elderly ; health
heart rate reduction ; ivabradine unloads ; ventricle ; heart failure
rvpo ; BiVP ; RS synchrony ; cp
anemia ; heart disease ; American College of Physicians
cardiovascular death ; hz ; exercise ; btes
heart failure ; high-density lipoprotein
Heart ; aortic blood flow ; doxorubicin

Myocardial pde ; expression ; hz
resistin ; acute anthracycline-induced cardiotoxicity
acute autonomic nervous system modulation ; qTV ; hz
BAT ; sympathetic outflow ; parasympathetic activity
end-stage renal disease ; systolic heart failure
Neurohormonal abnormalités ; pathophysiology ; congestive heart failure ; chf
echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
parasympathetic neurotransmission ; acetylcholinesterase
renal ; DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
Heart Failure ; Pathophysiology ; Medical Treatment Guidelines ; Nursing management
biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
canada
sympathetic activity ; ig ; myocardial washout
ventricle ;rv ; cardiac function ; medical
costs ; heart failure ; hz
radiological ; hz
mortalité ; bp ; mortalité
cardiopulmonary exercise ; heart failure
RV dysfunction ; weight ; fat ; body mass
chromatin subproteome ; heart
HR reduction ; beta blockers ; hf
protein kinase ; guanylate cyclase
confidence ; CIs
cPCs ; functional capacity ; heart failure ; hz
morbidité ; mortalité ;HF
Mortality ; aCS ; consultation
PSs ; social support ; btes
ctnt ; NT-probNP ; hz
Jehovahs Witness ; sickle cell disease ; anemia
miRNAs ; heart failure
physician continuity ; conditions ; hospital discharge
ca2 ; currents ; rad ; congestive heart failure
congestive heart failure ; chf
Health Buddy Program ; ed
mRI ; heart failure
cardiac stress ; β-AR drive
pulmonary artery ; pulmonary artery
dobutamine ; furosemide ; oxygen flow
LVf ; long-term mortality
Mediterranean ; DASh ; mortalité ; women ; heart failure ; Womens Health Initiative
cPCs ; diabetes
resistin ; anthracycline-treated breast cancer ; cardiotoxicity
transplantation ; circulatory assist device
Nursing-sensitive outcome ; change ; heart failure
therapeutic ; fluid overload

transcatheter ; surgery
resistin ; chemotherapy-induced heart failure ; mice ; breast
multivariable regression ; insurance ; comorbidities
black race ; mortalité
chelation ; heart ; iron
Timed up ; Go ; organ failure
heart failure
ST2
pressure ; ulcers ; surgical
hf ; plasty ; ms ; mva
pde ; refractory ; end-stage congestive heart failure ; chf
NYha
beta blockers ; mortalité ; heart failure
MT ; consultation ; abdominal

mortalité

complication
Stress ; doppler echocardiography ; pulmonary hypertension
ejection fraction ; cardiac resynchronization ; heart failure
co ; septal wall ; avd ; wall ; VVD
echocardiography ; ablation
circulating progenitor cells ; heart failure
etiologic ; RV failure ; ventricular dysfunction
systolic ; diastolic mitral leaflet ; organic lesion
myocardial diastolic dysfunction ; dt
ventricular ejection ; heart failure ; precapillary pulmonary hypertension
implantation ; aortic valve ; ventricular ; implantation
biventricular pacing ; left ; heart ; twist ; porcine ; right heart failure
cardiac nurses
closure
UM ;va ; rte
heart failure
coût-effective ; participatory ; health ; benefits
Czech Republic
INVESTs ; cardiac catheterization ; thrombotic obstruction ; right coronary artery
Western blots ; monoclonal antibodies ; Ser83 phosphorylation ; hz
hff ; sodium ; ventricular
echocardiographic ; invasive hemodynamic
heart failure ; chf ; sympathetic tone ; autonomic imbalance
California ; office of Statewide health planning ; patient ; discharge
right atrium ; mass ; prolapse ; tricuspid valve ; stenotic physiology
preoperative ; albumin ; ventricular ; implantation
functional capacity ; mwt
nursing ;HF
CHF ; explants ; sham ; explants
Chinese herbal medicine ; adjunctive treatment ; dilated cardiomyopathy ; heart failure
implantable ; cardioverter-defibrillator deactivation

économique ; af ; heart failure ; Québec ; Canada
cardiac Mena ; cardiac dysfunction ; abnormalités ; hypertrophy
electromechanical delay ; dyssynchronous heart failure
trastuzumab ; cardiac
bundle-branch block ;LBBB ;LBBB
Fontan failure ; systolic ventricular function ; liver disease
EH ; ch ; cardiac filling pressures
protein ; Western blot ; DNA fragmentation ; tunel ; autopsy
extracorporeal membrane ; oxygenation ; bridge ; recovery ; infarction-related refractory right heart failure
pacing-induced dilated cardiomyopathy
Heart failure ; mortalité ; society ; cardiovascular diseases
magnetically Levitated left ; ventricular Assist système ; HF
anticoagulation ; heart disease ; rate control
inotropic ; beta blockers ; heart failure
PAD ; ankle-brachial
HR ; ivabradine ;TAC
NT-probNP ; circulation ; hz
energy metabolism ; heart failure ; hypertrophied heart
mortalité ; morbidité ; cancers ; health-care budget
mechanical cardiac support ; renal
systolic function
ECmo ; VAD ; ECmo ;VAD
psoriasis ; smoked ; diastolic blood pressure ; body mass
HRQol
ed ; suburban hospitals ; New Jersey ; New York
cox models ; ST2 ; functional capacity
ms ; dynamique ; LV ; functional ms
transfusion ; mortalité
TM ; sts
HF
temps-varying Seattle ; Heart Failure
MADit-ct
neurological ; cardiovascular ; event-free ; confidence
BETs ;TAC ; hz
chemical instability ; cogeneration ; nitrite
aHF
consultations
HDl ; flow-mediated dilatation ; ete
dopamine ; nesiritide
NT-probNP
heart failure ; protein kinase ; expression
cox regression ; cardiovascular events ; psoriasis ; temps-dependent
cp ; hz
Paco2 ; cerebral blood flow ; carotid bodies
Functional ms ; medical treatment ; surgical
HF ; health service provision ; hf ; la
heart failure ; hz
renal dysfunction ; mechanical cardiac support
Heart failure ; hz ; chronic disease
management ; ventricular assist devices ; device therapies
hemoglobin ; health
cfa
Reasons
heart failure ; systolic heart failure
rhythm-control ; rate-control
CF ; lVAD ; AI ; heart failure
anemia ; heart disease
ventricular dilatation
coagulability
implanted
PB ; hf
iCD

HF
readmissions ; hospital ; pay-for-performance
echocardiography ; implantation
pro-adrenomedullin ;MR-proadm ; Ff
New York Heart association ; walk ; quality-of-life
ms ; ring annuloplasty ; ischemic ; MR ; LV
exercise intolerance ; heart failure
pathophysiology ; hz ; medical management
ventricular assist device ; extracorporeal membrane ; oxygenation ; renal ; heart failure
interleukin receptor ; ST2 ; beta-blocker ; heart failure
bNP ; NT-probNP ; biomarkers ; heart failure
Cardiorespiratory fitness ; body mass ; heart failure ; Cooper Center longitudal Study
vasopressin receptor antagonist ; tolvaptan ; japon ; heart failure
attention control
hospitals
hz
administration ; trastuzumab ; CHF

sudden cardiac death
biomarker-guided clinical
hospital mortalité
medical records
ejection fraction ;EF ; infarct ; collateral growth ; myocardial perfusion
Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
physique ; cardiovascular ; diabetes mellitus ; hypertension ; hyperlipidaemia
Circulation ; pro-B-type natriuretic peptides ; heart failure
heart failure ;HF ; ventricular ejection fraction ; hpEF
atrial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
HF ; cardiac murmurs ; blood pressure ; hg
ATP ; ROS ; mitochondrial respiration ; contractile
cardiac angiogenesis ; coronary perfusion ; cardiac fibrosis
instability ; heart failure ; ventricular tachycardia
tue ; COPd ; CHF ; cRF
pressure-overload-induced heart failure
Nursing ; social mandate ; nursing
HF ;VT ; beat-to-beat ; QT
biventricular dysfunction ; HeartMate
hemodynamically unstable ; cPR
end-stage heart failure ; implantation ; ventricular assist device
Pyridostigmine ; myocyte ; collagen density ; ventricle
cXL-1020 ; myocytes ; hearts
Exercise intolerance ; hf ;q
adenylyl cyclase ; g-protein coupling
systolic ;HF ; unclear etiology ; coronary angiography
implantable cardiac defibrillator
jugular venous pressure ; peripheral oedema
Heart failure ;HF ; condition
clinical ; rule ; CAD ; systolic ; hz
pump-exchange technique ; sternotomy ; cardiopulmonary bypass
surgery ; catheter-based revascularization
kccq
hz ; HF ; ms ; mva
ms ; medical treatment ; hz ; ms ; dynamic ; medical treatment
sonographic ; histological ; functional abnormalités ; gastrointestinal
parasympathetic function ; hz
hz
mechanical cardiac support ; renal function ; end-stage heart failure
EH ; systolic blood pressure ; renal impairment ; hypertension
chronic myocardial ischemia ; heart failure
Morpholino-based knockdown ; nucleolin ; expression ; morphological
hospital ; rehospitalization
HFpEF
CAD ; CAD
diabetes mellitus ; cardiovascular disease
HF-related cachexia ; RV ; body composition
rule
ECmo ; egFR ; egFR
haemodynamic ; pulmonary ; peripheral abnormalités
General hospital ; cardiac specialty hospital ; South Dakota
cognitive impairment ; mortalité
aCS ; MT ; VAD
CVd ; psoriasis
energy substrate metabolism ; hearts ; ac
SCHf
population-based Rotterdam ; psoriasis ; cardiovascular
HR ; tNF ; nbDMARD
Spironolactone ; hyperkalemia ; kidney injury
hereditary ; congenital abnormalités ; heart ; nontraumatic death
Fontan circulation ; skeletal muscle mass ; metabolic abnormalités

cardiovascular conditions ; hz
HeartMate ; lVAD
albumin ; lVAD
mineralocorruption receptor antagonists
right heart circulation ; right heart failure
MI ; late-onset ; MI ; hz
Fontan circulation ; sVR ; cardiac
lVAD ; biventricular
health insurance ; health system ; ue ; Food and Drug administration ; Mini-sentinel
NT-probNP ; ed ; acute heart failure
Blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic status ; whites
Bisphosphonate ; heart failure
réseau ; Cytoscape ; functional enrichment ; DAVID
Raf-MEK ; eurostag ; remodelling
costs
sustainability ; commissioning
clinical care ; maladaptive
patient safety
HF-induced remodeling ; EMd
mouse ; HF ; transition ; LV ; hypertrophy ; hd
heart failure ; preserved ejection fraction ; doppler ; echocardiography
natriuretic peptide ; biomarkers ; point de cac
anticoagulants ; antiplatelet ; heart failure ; atrial fibrillation
sympathetic ; parasympathetic activity ; hz
ventricular longitudinal systolic ; cardiovascular events ; atrial fibrillation
heart transplantations ;LV ; implantations ; heart failure
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
Xanthine oxidase ; ventricular systolic ; diastolic ; cardiac
bNP ;PAD ; bNP ; hz
heart failure ;HF ; Heart Failure Adherence ; retention Trial ;HARt
HF ; ejection fraction ;HFpEF ; hypertension
efficacy ; NYHA ; functional class ; quality-of-life
Myocardial infarction ; descending ; coronary artery
hf ; breathlessness ; fatigue ; fluid retention
immunodetection ; NT-probNP ; antibodies
Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
β-Blockade ; cardiac angiogenesis ; heart failure ; VEGF
myocardial ischemic events ; cardiac resynchronization therapy
aortic valve ; new-onset ; lVAD
unloading ; heart ; HR reduction ; systolic heart failure
spironolactone ; systolic heart failure
Heart failure ; medicine ; atheromatous coronary disease
Heart failure ;HF ; Latin America ; la ; health service planning ; HF
rehospitalization ; medicare ; fee-for-service beneficiaries ; skilled nursing facilities
hz ; ct
palliative
HFpEF ; medical history ; physique
oxidative stress ; GTPase ; Rac1 ; hearts ;ANS ; mice
circulateur ; insulin resistance ; monocytes ; inflammatory stimuli
cardiovascular death ; urgent cardiac transplant ; all-cause
medications ; heart failure ; NCd PINnaCLE
nonselective ; beta-blockers ; cardiac sympathetic activity ; heart failure
CHF ; emergency department ; ed ; intubated
mortalité ;LCx ;LAD ; two-vessel disease
RV dysfunction ; weight loss ; abnormal body composition ; hz
congestive heart failure
mitochondrial structure ; sarcomeric
Heart failure ; Emergency Department ; ed ; ed
degs ; non-ischemic ; ischemic heart failure
pp ; acr ; CMS
gut ; inflammation ; heart failure ; heart failure
heart failure ; ejection fraction
Intravenous iron ; heart failure ; iron deficiency
robot-assisted gait therapy ; Lokomat ; heart failure
stress ; conditions ; remodelling ; heart failure

readmission

transformed
psoriasis ;UV
NT-probNP ; hz ; immunoprecipitation ; mass spectrometric
Chromatin-associated proteins ; chromatin structure ; DNA ; gene expression
diastolic dysfunction ; hf
ventricle ; stroke ; ventricular ejection ; lVET
adrenergic receptor blockade ; heart failure ; hz
p ; complications ; therapy ; hz
transoesophageal echocardiography ; shunts ; thrombosis
mutant mice ; Hand ; heart ; muscles ; pathological hypertrophy
physician ; follow-up ; discharge ; readmission ; heart failure
dialysis ; echocardiographic
zf1 ; heart failure ; ejection fraction
ambulatory HF ; ventricular ejection ; fraction
QT ; qt ; qt ; cardiac death
Cross-talk ; heart ; adipose tissue ; cachectic heart failure ; body composition
arterial tonometry ; VET ; precapillary ; PH ; heart failure
heart ; magnetic resonance imaging ; chelation choices ; heart ; thalassaemia
PARADIGm-HF ; chronic heart failure ; heart failure ; cardiology
aim ; implantable ; cardioverter-defibrillator
New Zealand ; White rabbits ; renal DNx ; pacing-induced CHF
HDl ; CHF-NYHA-IIIb ; HDl
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
lVET ; death ; ICU
hemodynamic status
Cardiac failure ; diabetes ; molecular mechanism ; diabetes ; heart failure
noninvasive tools ; pulmonary hypertension ;PH ; heart failure
Beta-blocker
CHF ; therapeutic interruption ; neurohormonal systems
heart ; renal function ; spironolactone
microRNAs ;miRNAs ; heart failure
mRI ; tidal respiration ; myocardial ; heart failure
medical management ; hf
miRNAs ; cardiac remodeling ; heart failure
septal
cardiovascular disease ; ds

hospital ;AMI ; mortality
proteins ; acid
frailty ; heart failure ; hz
heart failure ; bisphosphonates
beta-blocker therapy
psoriasis ; cardiovascular disease ; cd
pde ; cardiomyocytes ; norepinephrine-induced hypertrophic
readmissions
cardiovascular disease
coût
POc ; technologie
Rhythm control therapy ; side effects
RAS-blocker ; hf ; hf
diastolic dysfunction ; filling pressures ; doppler echocardiography
Hemoglobin ; heart failure ; HF-ACtion
cardiac dysfunction ; subcellular ; metoprolol ; heart failure ; myocardial infarction
Myocardial collagen ; collagen cross-linking ; phosphorylation
Cardiac magnetic resonance ; heart failure ; ejection fraction
Systems proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cellular plasticity ; cardiomyocytes
cardiotoxicité ; doxorubicin ; anti-neoplastic agent ; cancers
heart failure ; ventricular ;LV ; ejection fraction
Fontan ;SAF ; catheterization
natriuretic peptides
AlphaLISa ; immunoassays ; NT-probNP
hf ; rheumatoid arthritis ;RA
financières ; hospital rates ; hz ; CMS ; conditions
implantable ; cardioverter-defibrillator deactivation
sinus ; rhythm ; antiplatelet agents ; anticoagulants
death ; c-statistics ; biological phenotype
Blocker ; cardiac angiogenesis ; cardiac function ; remodeling
index admission
expression ; Bax ; bcl-2 proteins
GDt ; GDt ; BAT
heart failure ; cCNka ; sNP
alendronate ; dose-dependent ; alendronate ; heart failure
transduction ; proteins
hz
Plasma ; hz
regulation of feeding ; nutritional ; anti-inflammatory effects ; CHF
clinical diastolic dysfunction
aCS ; oHT ; transplant ; MT ;VAD
RAS ; β-blocker
lifesaving drugs ; hf ; ejection fraction ;HFrEF
Kansas City ; Cardiomyopathy ; Questionnaire ; heart failure ; ejection fraction
heart failure ; ejection fraction ; hf
bNP ; NT-probNP ; coronary artery disease ;cad
fonctional mitral stenosis ; ms ; ring annuloplasty ; ischemic mitral regurgitation ;MR
heart failure-related hospitalisation ; ventricular ejection fraction
refractory congestive heart failure ; peritoneal dialysis
heart failure ; left atrial pressure
zSF1 ; obese ; zSF1 ; diabetic
doppler ; ventricular ; filling pressure ; systolic heart failure
Heart failure ; preserved ejection fraction ; hpEF ; cardiovascular morbidity
MT ; VAD ; aCS ; consultations ; mortalité
LV ; diastolic dysfunction ; figure ; hf
Mammalian enabled ;Mena ; cytoskeletal actin dynamics ; heart failure ; hz
Gastrointestinal bleeding ; ventricular assist devices
ARNI ;angiotensin-receptor neprilysin
Fes ; preserved ejection fraction ; hpEF
Myxomas ; cardiac benign tumors ; atrium
nicorandil ; cytotoxic effect ; doxorubicin ; Ehrlich carcinoma
ambulatory iCD ; mortalité ; multivariable regression
Heart failure ; ejection fraction ; hf ; cardiovascular reserve
Renal denervation ; dnx ; CHF
physician ; follow-up ; discharge ; physician continuity ; heart failure
hyperkalemia ; kidney ; spironolactone
myocardial ; pde2 ; intracellular antiadrenergic ; hz
carotid ; intima-media ; psoriasis
coronary occlusion ; collateral growth ; stent occlusion
HF
VO2 ; joint effect
avantages ; spironolactone ; medications
RV dysfunction ; cardiac cachexia
eCG ; ct
Mechanical dyssynchrony ; QRs ; ct
pharmacologic ; clinical trials ; pharmacologic
ie ; heart failure ; hz ; ct-d
chronic heart failure ; Hungary
breast cancer ; trastuzumb-related CHF
Remote monitoring ;RM ; heart failure

NT-probNP
PVf ; PB ; BP
transfusions ; heart disease

sST2 ; cardiovascular
ECCT
aerobic capacity ; left-hand grip ; strength ; body weight ; waist circumference ; anxiety
Myocardial loss ; iRS1 ; RS2 ; heart failure ; maPK ; insulin resistance
heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
lVET ; ICU ; precapillary ; PH ; heart failure
Renal dysfunction ; all-cause mortalité ; cardiovascular events ; caBG
isoprenaline infusion ; SDQT ; hz
heart failure ; ejection fraction ; myocardial infarction
coronary artery disease ; systolic heart failure ; etiology
arterial compliance ;TAC ; end-systolic elastance ; ees
aldosterone antagonist ; heart failure
Genetic susceptibility ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; HFpEF
Renal dysfunction ; long-term mortalité ; myocardial infarction ; coronary artery ; grafting ; cag
Biventricular support ; HeartMate ; lVAD ; CentriMag VAD ; mortalité
angiogenesis ; post-myocardial infarction ; heart ; heart failure
pde2 ; hearts ; β-AR
surgery ; medical treatment ; hz ; hypertension ; vasodilateurs ; diuretics
egFR ; diuretics ; hypertension ; ESRD
heart failure
point-of-care ; NP ; ed ; outpatient ; acute heart failure
eEO-cFUs ; mortalité
trastuzumab ; CHF ; nontrastuzumab
anemic ; iron-deficient ; heart
HR ; beta-blocker
acute heart failure ; HF ; heart failure ; hz
psoriasis ; atherosclerosis ; cardiovascular events ; psoriasis
HF ; remodeling ; EMd ; dyssynchronous failing heart
Pyridostigmine ; vascular endothelial growth ; protein ; ventricle ; myocardial angiogenesis
idiopathic ; dilated cardiomyopathy
cardiac growth ; plasticity ; developmental chromatin remodeling
protocol ; CHF ; international Classification of Diseases
MEDline ; eEMBAse ; cochrane ; clinical trial registries
egFR ; VAD ; ECmo ;VAD ; ECmo
Ea ;TAC ; HR ; ees ; ivabradine
ERC ; epicatechin ; muscle
Robot-assisted gait therapy ; Lokomat ; heart failure
cf ; HF mortality ; HF
RV dysfunction ; body mass ; fat mass ; cachexia
HF ; HF
myocardium ; expression ; pKA
Care management ; content-driven telehealth technologie ; health outcomes ; high-cost Medicare
hf
exercise ; health benefits ; cardiac disease ; heart failure
HDl ; CHF ; HDl-mediated vascular effects
HF ; risk factors ; HF mortality
hz ; cPGs
lVAS
biomedical reasons ; nonprescribing
black race ; hz ; cardiovascular mortality
dopamine ; nesiritide

implants ; transseptal catheterisation ; transoesophageal echocardiographic guidance ; anaesthesia
Isoelectric ; RIα ; Ser77 ; Ser83 ; phosphorylation
NT-probNP ; MR-proanp ; MR-proadm
tNF ; HF ; hospital admissions ; nbDMARDs ; RA
myocardial infarction ; m ; heart failure ; hz
Heart rate reduction ; heart failure ; ejection fraction ; beta-blocker hypo-response
HeartMate II ; biventricular support ; HeartMate II implantation
ST-segment-elevation ; MIs ; Killip class ; conditions
mADIt-ct ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy ; nCT
brain natriuretic peptide ; bNP ; creatinine ; natremia
RAS ; hypertension ; nephropathy ; congestive heart failure
ms ; valve plasty ; degenerative MR ; LV
elastic N2Bus ; PEvk
heart failure ; Heart failure ; public health ; europe ; nord America
Nicorandil ; mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats ; cardioprotection
HeartMate ; ventricular assist system ; lVAS ; heart failure
cXL-1020 ; hno ; inactive ; cXL-1051
arterial ; elastance ; resistive ; pulsatile ; heart ; pressure
pharmacologic management ; acute HF ; chronic HF
proteomics ; chromatin-associated proteins ; detergent
heart failure ; mechanical support devices ; Cardiology-cardiovascular surgery ; commission ; Heart failure
heart failure ; implantable cardioverter-defibrillator
Self-Care ; Heart Failure ; graphe ; psychometric
atrial fibrillation ; carvedilol ; metoprolol
SDQT ; SD ; RR ; dt ; qTV ; heart
gastrointestinal bleeding
readmission ; patients ; heart failure
Logistic regression ; death
egFR ; VAD ; ecmo ;VAD ; renal
aUCs ;septal ;septal ; QRs ; resynchronisation
physique ; mortalité ; hz ; noncardiologist
LV ; ejection fraction ; PCWP
diuretics ; hz
readmission ; hospital stay ; congestive heart failure ; United States
IVc ; co ; twist ; apical rotation ; RS ; RS synchrony
CHF ; ed ; CHF ; intubated
emergency department ; acute heart failure ; trials ; Collins
zebrafish ; nucléaire ; genomic reprogramming
physician ; class I recommendations ; benefits
grs ; hz ; CV
sST ;low-dose ; sST ;high-dose
ms ; cardiac events
ejection fraction
hf ;AMI ; mortalité

mortalité ; hospitals
nurses ; benefits ; multisite study ; magnet ; research
hf ; drug treatment ; PAf biosynthetic enzymes ; lyso-paf-AT
cardiac magnetic resonance ; t1 mapping ; invasive hemodynamic
avantages ; hz ; ejection fraction ; pEF
mouse ; hd ; salt loading ; uninephrectomy ; ANG ; infusion
RAS ; neprilysin inhibition ; change ; heart failure ; systolic dysfunction
tidal respiration ; administration ; gadolinium-chelate contrast agent
Medicare ; inpatient ; hf ; admissions ; acute care hospitals ; france
idiopathic dilated cardiomyopathy ; tuscany
Morbidité ; mortalité ; HFpEF ; hf ; EF
DAPc ;dystrophin-associated protein complex ; sarcomeric
dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; ROe ; acute heart failure
catheter ablation ; atrial fibrillation ; heart failure ; ejection fraction
eCG ; ion channelopathies ; cardiomyopathy
heart failure ; hz ; inpatient ; outpatient
hz ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
iron ; heart failure
Erythropoiesis-stimulating agents ; anemia ; heart
knockdown ;BET ; bromodomain-containing protein ; bd ; cardiac tissues
in-trial resource utilization ; costs ; Québec Health Insurance Board ; costs ; Ontario Case Costing Initiative
mitral valve ; plasty ; mitral regurgitation
carvedilol ; metoprolol ; heart failure
HF ;heart failure ; t2d ;Type 2 diabetes ; Skm ;keletal muscle
public health ; air pollution ; cardiovascular health
molecular biomarkers ; pathophysiology ; chronic HF
cardiopulmonary ; quality of life ; muscular strength ; quadriceps force
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat ; metabolic
NT-probNP ; antibodies ; nonglycosylated
University of Connecticut ; Heart Failure Center ; cardiologist ; heart failure
baseline serum creatinine ; serum potassium
pde ; weight ; diuretic response ; peripheral edema
echocardiographic ; cardiac resynchronization therapy ; ct
HeartMate ; lVAD ; CentriMag VAD
hf ; MI ; ejection fraction ;EF
anemia ; chronic heart failure ; hz
Hum-retn ; mice ; cardiac mRNA ; inflammatory ; cell adhesion ; Retn
chromatin subproteomes ; heart failure ; proteins ; chromatin structure
HFpEF ; kccq
nbDMARD ; tNF
avantages ; vent failure
af ablation
end-stage heart failure ; mechanical cardiac
Chronic heart failure ; transforming growth factor ; functional decline ; atrial ; explant-derived
rv ; ventricular dysfunction
change ; readmission
Mortality ; inpatient admissions ; emergency department ; ed
économique models ; mandatory ; lVAD
echocardiographic score ; ct
ejection fraction
If-channel inhibition ; hemodynamic ; heart failure ; ejection fraction
Cardiac ; insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
nutritional abnormalités ; CHF ; fat ; carbohydrates
pigs ; inferior vena cava ; icc ; snared ; co
doxorubicin ; ip ; induction ; serum resistin ; Hum-retn ; mice
costs ; high-volume physicians ; hospital
rheumatic ; ms ; mva


HF ; pyridostigmine ; stroke ; ejection fraction ; cardiac output ; contractility ; ventricle
myosin binding ; protein-c ; phosphorylation ; ser23 ; troponin ; phosphorylation ; hz
aldosterone receptor antagonists ; morbidité ; mortalité ; systolic heart failure
uPR ; protein kinase ; ER kinase ;PER ; calreticulin ; CHOp ; hz
hf ; exercise ; HR ; beta-blocker therapy
echocardiographic ; pro-brain natriuretic peptide
temps ; ESRD ; death ; ESRD ; death ; ESRD
rcts
heart failure ; heart failure ; nurses ; cardiology services ; mortalité
heart failure ; hz ; cardiopulmonary exercise ; anaerobic
preoperative renal dysfunction ; stroke ; myocardial infarction ; heart failure ; caBG
XO ; cardiomyocyte bioenergetics ; LV ; aCF
carvedilol ; thromboembolic events ; heart failure ; β2-receptor haplotype
pyridostigmine ; methylatropine ; propranolol ; cardiac sympathovagal balance
PAf ; metabolic enzymes ; heart failure
trastuzumab ; cardiotoxicité ; congestive heart failure ; chf
Phosphodiesterase-2 ; hearts ; beta-adrenergic ; cardiomyocytes
lipolysis ; energy expenditure ; natriuretic peptides ;NPs ;cc
hazards ; health behaviors ; health status ; confidence
eas ; rhythm control therapy ; af ; cardiovascular complications ; af
hearts ; Mena ; cardiac injury ; Mena ; hz ; pathophysiology
sCN5a ; uPR ; downregulation ; cardiac ; hz
AIN oUTCOME ; grs ; index beat ; CV ; cox
VAD ; ECmo ;VAD ; ECmo
passage ; PASp ; shift ; nonsurvivors ; PASp ; tAPse
ventricular ;RV ; left ventricular assist device ; lVAD
albumin ; nutrition ; inflammation ; hepatic ; lVAD ; implantation
ST2 ; discrimination
post-hCT ; CHF ; hCT ; City of Hope
Genes ; non-ischemic ; ischemic ; heart failure ; biomarkers ; heart failure
CHF ; infarcted animals ; ventricle ; end-diastolic pressure ; hg ; scar
Women ; Health Initiative ; hf ; contact
Peak oxygen consumption ; oxygen pulse
dialysis-dependent ;HF ; ct ; implantation ; complications
RV ; pathophysiologic ; RV dysfunction
recreational athletes ; cardiac deaths ; atherosclerotic CAD
air pollution ; cardiovascular health ; acute myocardial infarction
économique ; NHs ; behavioural-change ; chronic disease
CV ; non-fatal stroke ; heart failure
biomarkers ; molecular dysfunction ; hz
kccq ; Kaplan-Meier curves
ct-d ; IE ; defibrillator-only therapy
HR ; dynamiques ; temps-domain ; HR ; risk

Obesity ; diabetes mellitus ; metabolic risk factors ; heart failure ; ejection fraction
therapy ; atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
hypoalbuminemia ; postoperative mortality ; ventricular assist device ; lVAD ; implantation
AMI ; heart failure ; kidney infection ;UTI
Cardiopulmonary ; echocardiographic ; myocardial function ; ventricular filling
coronary revascularization ; hemodynamically stable ;ICU
echocardiography ; ste ; BiVP ; ventricular pressure ;RVpo
pathophysiologique ; renal underperfusion ; renin- angiotensin-aldosterone
Olmsted County ; Minnesota ; MI ; hf
proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
neurohumoral blockers ;HF ; co-morbidity burden
death ; hf ;AMI ; discharge
CAD ; CAD
vascular endothelial growth factor ; edf ; transition ; compensatory hypertrophy ; cardiac failure
ventricular ejection ; mortality ; heart failure ; Heart Failure ; israel
medical hospitalization ; hz
icc ; multicenter Automatic Defibrillator implantation ; Trial-Cardiac resynchronization Therapy
Testosterone therapy ; exercise ; heart failure ; testosterone
Health Buddy ; chronic obstructive pulmonary disease ; mortalité ; congestive heart failure
RAS ; doppler ultrasonography ; tomographic angiography ; magnetic resonance ; angiography
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
atrial fibrillation ; af ; heart failure ; hz ; stroke ; anticoagulation
echocardiographic ; LV ; reverse remodeling
perk ; sCN5a ; kv ; mRNA ; mRNA splice
bottleneck stent ; myocardial infarction ; antiplatelet
sex ; EF ; bNP ; hf ; bNP ; sex ; EF
Trastuzumab ; CHF ; nontrastuzumab ;hazard
dysfunction ; rad ; kv ; congestive heart failure
salt loading ; uninephrectomy ; ANG ; infusion ; cardiac ; mice ; hz
Mena expression ; hf ; Mena ; cardiac pathophysiology
LVf ; long-term mortality ; acute decompensated HF
Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
hz ; aami ; mortalité
systolic heart failure ; spironolactone
uPR ; mRNA splice ; cardiac ; hz
diuretic efficacy ; neurohormonal activation ; fluid
BETs ; transcriptional pause release ; transcription ; pathological stress
lVAD ; transplantation ; budget
LVEF ; LVEF
apoptosis ; heart failure
functional enrichment ;regulation ; cell death ; degs
eCG ; atherosclerotic CAD ; cardiac death
HR reduction
mice ; LV ; fractional shortening ; lung weight
atrial fibrillation ; atrial fibrillation ; Stroke
Frailty ; heart failure ; hz ; biological phenotype
ms ; valve plasty ; annular size reduction ; MR ; LV
idiopathic ; dilated cardiomyopathy
ventricular ;RV ; body composition ; heart failure ; hz
American College of Cardiology ;American Heart association ; RAS ; RAS
ARNI ; cardiovascular mortality ; hospitalisation ; heart failure
quadriceps force
implantable ; cardioverter-defibrillator deactivation ; heart failure
EO-cFUs ; CD34 ; vf2 ; mortalité ; nondiabetic
MS ; valve plasty ; degenerative MR ; LV
anaerobic metabolism ; respiratory
HF ; therapy
myocardial DD ; muscle strip stiffness ; hypophosphorylation
NP ; POc ; NPs
etiology ; comorbidities
high-volume ; readmission
crédits ; intestinal morphology ; permeability ; absorption function ; CHF
expression ; cardiac hypertrophy ; proteins ; nucleolin
benefits
Blood pressure ; arm cuff ; stroke ;SV ; ejection fraction ; end-diastolic ; echocardiography
Kansas City ; Cardiomyopathy Questionnaire ; kv ; hz ; EF ; HFpEF
biventricular support ; HeartMate ; lVAD ; CentriMag ; ventricular assist device ; VAD
annular plane systolic excursion ; pulmonary ; arterial systolic pressure ; heart failure ; ventricular contractile
fibrosis ; heart failure ; myocardial tissue ; ventricular tissue ; trichrome blue histologic
bt ; dt ; cost-effectiveness ; bt
expenditure ; health ; gross ; income ; hz ; la

blood pressure ; lipid-lowering ; smoking ;RAS
SDQT ; HFVT ; HFVT ; hNorm ; fixed-rate atrial pacing
coûts ; coût-effectiveness
af ; pharmaceuticals ; hf
IEs ; ct-d ; heart failure
bp ; inhospital mortality
technique ; diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
implantable cardioverter-defibrillateurs ;ICds ; mortalité ; cardiac resynchronization therapy ; ct
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal
Vascular endothelial growth factor ; beta-blocker ; therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
NT-probNP ; dyspnea ; ventricular dysfunction ; ed
contractile function ; LV ; dilatation ; end-diastolic pressure ;wall stress ; lung weight
Circulation progenitor cells ; cps ; endothelial repair ; cardiovascular
hz-ACtion ; hgb ; HRQol ; kccq
pathological remodelling ; heart ; cardiac hypertrophy ; hz ; fibrosis ; inflammation
Caucasian ; sNP ; renal chloride channel gene ; cCNka
HFpEF ; echo-doppler cardiography ; invasive haemodynamic assessment
LV ; remodeling ; diastolic properties ; XO inhibition ; heart failure
RAS ; β-blocker ; hf ; HFpEF
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
DASh ; diastolic ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
Yorkshire swine ; implanted ; pacemakers ; ventricularly paced ; heart failure
multiparametric echocardiographic score ; reverse remodeling ; ct
heart rate ; hz ; ivabradine ; systolic heart failure
biomedical treatment ; chm ; biomedical treatment ; dCM ; heart failure
Cardiovascular Outcomes ; Renal Atherosclerotic Lesions ; coRAL ; stenting ;RAS
centrifugal flow ; pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow ; pulse
mitochondrial complex ; activity ; ac ; phosphocreatine ; ATP
Mediterranean ; Dietary Approaches to Stop hypertension ;DASh ; mortalité ; postmenopausal ; hz
left-to-right ; interatrial shunting ; heart failure ; ejection fraction
mortalité ; heart failure ; hz ; implantable cardioverter defibrillateurs ;ICds
Physicion ; medically managed diseases ; hz
frail ; biological
eplerenone ; HF-ref ; hyperkalemia ; wf
acute heart failure ; HF
RM ; discharged ; heart failure
LBBB ; implantable cardioverter defibrillator-ct
mdp ; change
embryonic gene programs ; pathological heart disease ; transcription factors ; gene
hff ; longitudinal outcome-monitoring ; cardiac
sST ;low-dose ; sST ; cardiovascular events
skeletal muscle ; heart failure ; diabetes ; epicatechin-rich cocoa
QRs ; morphology ; cardiac resynchronization therapy ; ct
exercise-induced PASp ; hg ; PASp ; PASp
heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; medical treatment ; heart failure
POc ;NP
mortalité ; readmissions ; costs
LBBB ; QRs ; implantable ; cardioverter ; defibrillator-ct
echocardiography ; cardiac diameters ; cardiac function
MEDline ;EMBAse ; PsycINFO
life ; functional capacity
trial ; academic medical center
ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ; hz
systolic ;HF ; cXL-1020 ; left ; heart ; filling pressures ; systemic vascular resistance ; cardiac ; stroke
cardiovascular death ; stroke ; heart failure ; myocardial infarction
Cardiac-resynchronization therapy ; ct ; morbidité ; mortalité ; chronic systolic heart failure ; QRs
perk ; destabilization ; sCN5a ; kv ; mRNAs ; transient receptor ; m7 ; tm7) ; mRNA
implantable cardioverter-defibrillator ; Heart Function Clinic ; University Health Network ;Toronto ; Canada
exercise-induced PASp ; pulmonary hypertension ; ventricular contractile
MI ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
antagonists ; inhibiteurs ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
outpatient ; heart failure ; hospital discharge ; readmissions
antiplatelet agents ; anticoagulants ; vascular diseases
Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; v ; cardiac
myofiber dynamics ; myofiber ; emd ; dyssynchronous HF
ankle-brachial index ; pulse-wave ; coronary artery ; calcium
truncated na+ channels ; unfolded protein response ; uPR ; scc5a ; electric remodeling ; hz
intermacs ; interagency Registry ; Mechanically Assisted Circulatory Support
international Right Heart Foundation ; defects ; right heart failure
Mice ; cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; ac
HF ; HF ; epidemiology ; SH ; cd ; rheumatic fever
caloric ;diet ; aerobic exercise ; exercise ; Qol ; obese ; hf
heart failure ;HF ; hemodynamic disorder ; dysfunction ; interconnected molecular pathways
medications ; heart failure ; ejection fraction ; outpatient
hf ; exertional ; diastolic filling ; temps ; heart rate
mice ; cardiac myocyte-specific ; Mena ; overexpression ; tgtetMena ; cardiac
allopurinol ; LV ; contractile ; XO-mediated ROS ; myofilament ; sensitivity
therapy ; comorbidities
af ; heart failure ; financier burden
rehospitalization ; Medicare ; hospital claims ; Medicare ; post-acute care transfer policy
heart failure ; compliance ; etidronate ; alendronate
metabolic exercise ; cardiac ; kidney
physical activity ; cf ; hz
ete ; HDl-mediated protective effects ; molecular pathways ; heart failure ; chf
physicians ; management ; patients ; advanced heart failure ; therapeutic
heart transplant ; ECCT
body weight ; FM ;f ;cc

ventricular ejection fraction ; ventricular diastolic end diameter
eccentric ; concentric left ventricular hypertrophy ; heart failure ; ejection fraction
ventricular ejection fraction ; heart failure ; preserved ejection fraction ; hpEF
β-adrenergic receptor blocker ; myocardial perfusion ; neoangiogenesis ; failing heart
hgb ; kccq ; hgb ; HRQol
bone morphogenetic protein ; expression ; rRNA transcription ; heterochromatic chromatin
dopamine ; nesiritide ; renal
actin cytoskeleton ; mitochondrial ; metabolism ; glycolysis ;gluconeogenesis
resistin ; biomarker ; anthracycline-induced cardiotoxicity ; heart failure
ventricular biopsies ;issueFAXs ; technologie
systolic HF ; Danish Heart Failure ; new-onset ; ESd ; Danish Registry on Dialysis
ventricular assist devices ; lVADs ; heart failure ; pump dysfunction ; pump replacement
bp ; diastolic dysfunction
hART ; HFpEF ;HF ; reduced ejection fraction ;HFrEF
techniques ; systolic function ; HFpEF ; long axis function ; exercise
hf ; mortalité ; hazard ; mortalité
AAs ;HF ; hyperkalemia ; hypokalemia ; spironolactone ; as ; clinical benefit
g-protein-coupled ; receptor kinase-2
NT-probNP
scc5a ; angleII ; expression ; uPR ; downregulation
ST2 ; amino-terminal ; natriuretic peptide
sST ; high-dose ; sst2 ; b ; cardiovascular
anemia ; iron deficiency ; MEDline ; cochrane Library
neurohormones ; adipokines ; body composition ;cc ; fat free mass ; flm ; fat mass ;FM
cardiac plasma membrane ; s1PR1 ; overstimulation ; heart failure
Sprague-Dawley ; sham ; aCF ; allopurinol
myocardial collagen ; myocardial delayed enhancement imaging
saxagliptin ; sitagliptin
fully magnetically levitated lVAS ; mortalité ; Seattle ; Heart Failure
change ; hospitals
kccq ; internal consistency ; HFpEF ; ronbach
implantable ; cardioverter defibrillator-ct ;LBBB ; QRs
principal ; clinical trials
alendronate ; etidronate ; raloxifene-tre
Chemotherapy ; trastuzumab ; CHF ; international Classification of Diseases ; healthcare Common Procedure ; coding système codes
heart failure ;HF ;HF ; ventricular ejection fraction ;LVf
dogs ; tachypacing-induced ; hz ; contractility ; end-systolic elastance ; venoarterial dilation
ct
transplantation ; consultation ; MT ; consultation
transplantation ; LV ; implantation ; heart failure
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation ; creatine kinase activity
correlation coefficient ; icc ; kappa coefficient ; change ; mdp
Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs
heart failure ; Heart Failure ; controlled Trial Investigating Outcomes ; exercise ; hz-ACtion
biomedical treatment ; chm ; biomedical treatment ; dCM ; heart failure ; PubMed
Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
Biventricular pacing ;BiVP ; cardiac output ; co ; cardiac surgery
New York Heart association ;NYha ; chronic heart failure ; reduced ejection fraction ; Canadian special access programme
AlphaLISa immunoassays ; antibodies ; NT-probNP
creatinine ; bp ; furosemide ; oxygen flow ; dobutamine ; norepinephrine
expression ; mistargeting ; regulation ; rad ; q66p ; GK ; efficacy
Myocyte hypertrophy ; heart failure ; gene expression ; DNA
catheter ablation ; af ; hf ; ventricular ;LV ; ejection fraction
Cardiology ; national Cardiovascular Disease Registry ; practice Innovation ; Clinical Excellence
transitions ; readmission ; congestive heart failure ; Midwestern state ; South Dakota
sts ; hz ; medical support ; all-cause mortality ; discharged ; heart failure
surgically induced myocardial infarction ; heart failure ; bisoprolol
transitions ; self-management ; out-patient ; follow-up ; health care system
CHF ; cardiac explant
tachycardia ; atropine ; cardiac vagal tone ; CHF-DNx ; CHF- inv
cardiomyocytes ; mechanical ; humoral ; myocardium ; conditions ; stress
biological phenotype ; medical records ; frailty
BB therapy ; dose-related benefits ; sst2 ; heart failure ; BB
ESRD ; outpatients ; systolic HF ; egFR
pacse ; PASp ; length-force ; RV ; LV
tue ; apoptotic cells ; tue-positive cells
functional efficacy ; hno ; myocardial function ; hz
biventricular support ; VADs ; explanted
Peritoneal dialysis ; p ; diuretic resistant volume ; heart failure ; hz
left-to-right interatrial shunting ; heart failure ; ejection fraction
hno ; cXL-1020) ; myoctyes ; hearts ; heart failure ; hz
physique ; bmi ; weight ; heart rate ; rhythm ; lying ; standing ; blood pressure ; auscultation ; valvular disease ; pulmonary congestion
myocardial extracellular matrix ; cardiac magnetic resonance ; pathobiology ;pathophysiology
aldosterone antagonist therapy ; heart failure ; post-myocardial infarction ; heart failure ; ejection
Nicorandil ; heart ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin ; cardiotoxicity
heart failure ; ventricular ejection ; spironolactone ; Kaiser Permanente ; Northern California
SDQT ; HFVT ; hNorm ; β-adrenoceptor ; blockade ; esmolol
heart failure ; CHARM ;Candesartan in Heart Failure ; Mortality
heart failure ; preserved ejection fraction ; hf ; heart failure ; overweight
Renal dysfunction ; heart failure ; hz ; end-stage renal disease ; edf
echocardiographic ; LV ; reverse remodeling ; LV ; end-systolic
Peripheral artery disease ;PAD ; heart failure ; hz ; hz ;PAD
readmission ; heart failure ; hz ; acute myocardial infarction ;AMI ; pneumonia
peripheral muscle pump ; cardiac filling ; subpulmonary ventricle ; Fontan circulation
preoperative renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; coronary artery ; grafting
Fontan ;PF ; catheterization
ms ; subvalvular ; dynamic ; ms ; ring
ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
Lancet ; anoop Shah ; air pollution ; heart failure ; morbidité ; mortalité
anemia ; HF ; health-related quality of life ; hQol ; HF
cell therapy ; chronic heart failure ; chf ; explant-derived progenitor cells
mRI ; dyssynchronous nonfailing ;HF ; canine electromechanics ; remodeling
American College of Physicians ; acp ; anemia ; iron deficiency ; heart
cell senescence ; active ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
drug-free
chronic heart failure ; hz ; exercise
histological ; capillary ; coronary ; b-treated ; ad-flk ; b-treated ; ad-c
physician ; mortalité ; internists ; cardiologists
shuttle walk ; body mass ; hand grip strength
protocol-driven POc ;NP ; consultation ; ed ; throughput
Troponin ; n-terminal pro-B-type natriuretic peptide ; biomarker ; heart failure ; atherosclerosis
tachycardic response ; methylatropine ; vagal tone ; bradycardic ; propranolol ; sympathetic tone
rv failure ; chronic pulmonary arterial hypertension ; pde ; acute pulmonary embolism
cardiac resynchronization therapy ; ct ; heart failure ; hz ; QRs ; ejection fraction ;EF
Fractional flow ; positron emission tomography ; ischemia ; bottleneck ; stenting ; ventricle ;LAD
mitochondrial oxidative phosphorylation ; creatine kinase activity ; oxidative stress ; DNA fragmentation ; ultrastructural changes
spironolactone ; hyperkalemia ; kidney injury
mortalité ; mortalité ; cardiovascular mortality ; hz ; cox models
cardiac transplant ; ecc ; transplant pool ; donors ; transplant
medical Therapies ; Cardiac Function ; Breath ; Lung congestion ;ACTRN
septum ;systolic ; thickness ; posterior wall thickness ; internal diameter ; metoprolol
obese ; hff ; caloric ; aerobic exercise ; VO2
économique ; Patient management ; Heart Failure ; coût-effectiveness ; disease management ; heart failure
prospective HF ; HF ; EF ; HFpEF
BAT ; n-terminal pro-brain natriuretic peptide ; hz
hz ; mortality ; am ; CHF ;LV
injection ; natriuretic peptide ; atrial natriuretic peptide ; natriuretic peptide
preoperative ; hypoalbuminemia ; albumin
rv ; pulmonary embolisme ; mortalité
electrical activation ; remodeling ; dyssynchronous heart failure ; hz ; electromechanical behavior ; heart
heart failure ;heart team ; cardiologists ; cardiovascular surgeons ; medical staff
Baroreflex sensitivity ; temps ; heart rate variability ; hv ; CHF-inv ; sham-inv ; sham ; renal DNx
bisphosphonates ; alendronate ; etidronate ; heart failure ; refill compliance
nurse ; cognitive impairment ; physician ; discharge ; elderly ; heart failure
HF-ACtion ;HF ; ejection fraction
Chinese herbal medicine ; chm ; adjunctive treatment ; dilated cardiomyopathy ; dm ; heart failure
serum resistin ; anthracycline-containing chemotherapy ; cardiotoxicité
sst2 ; cardiovascular
rad ; q66p ; cardiomyopathy
ventricular structure ; geometry ; fiber ; sheet ; conduction ; wall stiffness
SDQT-to-SDRR ; HFVT ; hz
renin-angiotensin system blocker ; beta-blocker ; heart failure ; ventricular ejection fractions
electrical stimulation ; peripheral muscles ; endothelial ; heart failure ; ventricular ejection fraction
cardiac transplantion ; ECCT
diastolic dysfunction ; pathophysiology ; HFpEF ; non-diastolic abnormalités ; cardiovascular
EMd ; dyssynchronous HF ; remodeling
hypertension ; hf ; DASh ; rte ; sodium
doxorubicin-induced cardiotoxicity ; Hum-Retn ; mice ; littermate ; résistance ; rte
remodeling ; arrhythmia substrate ;AMI ; HR ; arrhythmia
heart failure ;HF ; hz
hz ;AMI ; pna ; mortalité
hypertension ; hg ; diabetes mellitus ; systolic ; diastolic murmurs
tAPse ; PASp ; nonsurvivors ; hf ; HFpEF ; résolution
histone acetyltransferases ;erasers ;histone deacetylases ; cardiac
NT-probNP ; mortalité ; hz
Haematopoietique cell transplantation ; ht ; congestive heart failure ; chf ; pre- ht ; anthracyclines
cardioprotective ; nicorandil ; hemodynamic ; mitochondrial dysfunction ; doxorubicin
mir-25 ; cardiac dysfunction ; murine ; myocardium ; heart failure ; Hand2-dependent
carvedilol ; β-blocker ; β-blocker ; metoprolol ; thromboembolic events ; heart failure
cox regression models ; propensity score ; glucocorticoid ; hz ; loop diuretics
preoperative albumin ; mortalité ; lVAD ; implantation
dyssynchronous ; hz ; electromechanical delay ; edd ; temps ; myocyte depolarization ; myofiber
Beta blockers ; mortalité ; readmissions ; heart failure ; ejection fraction ; hf ; heart rate ; hz
bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke ; Rank
Dialysis ;HF ; mortalité ; hz
fonctional electrical stimulation ; fes ; exercise ; emotional stress ; endothelial ; heart failure ; impaired systolic
ejection fraction ; cardiac ; inotropes ; inotrope-dependent ; medical management ; transplant
systolic heart failure ; QRs ; ct ; heart failure
résolution ; High-density lipoprotein ;HDl ; endothelial-protective effects ; endothelial cell ; ec ; nitric oxide
8-fluo-cAMP ; phosphomimic ; ser77 ; ser83 ; mutant ; RIα ; kd ; double mutant ;WT ; RIα
admission to discharge ; vent failure ; hz ; Nursing Outcomes Classification ; noc
insulin resistance ; diabetes ; insulin receptor substrates ; rs ; insulin-signaling ; cellular metabolism
dgs ; non-ischemic ; heart failure ; heart failure
hf ; saxagliptin ; sitagliptin ; antihyperglycemic agents
QRs ; cardiac resynchronization ; resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ;RAF
heart ; magnetic resonance ; imaging ; chelation choices ; patient compliance ; heart failure ; arrhythmias
eds ; discharge ; heart failure ; ED ; readmissions ; ED
anticoagulation ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ; af
nitroxyl ; hno ; Angeli ; salt ; inotropic ; lusitropic ; vasodilator ; cAMP
expression ; Bax ; bcl-2 ; mRNA expression ; heart failure ; bcl-2/Bax
cPCs ; early-outgrowth colony-forming units ; e-cFUs ; CD34 ; vEGFR2 ; CD133
ejection fraction ;EF ; pre-PD ; NYha ; class IIIb ; ventricular dysfunction
lVADs ; hei ; hm ; HeartWare ; bt ; dt
heart disease ; hz ; surgical palliation
ct-d ; IE ; IC ; ct-d ; IEs
fréquence ; biological phenotype ; strength ; physical exhaustion ; weight
transplant ; pde ; hf ; volume management ; pde
SAF ; abnormal liver ; changes ; nodularity
biomarker ; biomarker-guided clinical trial ; multimarker-based
right atrial myxoma ; embolisme ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
acute right heart failure ; therapy refractory cardiogenic shock ; heart ; corporeal membrane oxygenation ; ecmo ; cp ; ICU
cardiac ; VEGF expression ; Akt ; endothelial no synthase activation ; drug-untreated ; failing hearts
heart failure ; ventricular systolic dysfunction ; BB
DASh ; rs ; brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular ; echocardiographic
cardiac ; insulin-resistance ; ac ; insulin-stimulated ; glycolysis ; glucose oxidation ; plasma membrane ; glucose transporter
Gene expression ; gse9128 ; Gene Expression Omnibus ; heart failure
exercise-induced PASp ; ventricular contractile reserve ; exercise-induced PASp
expression ; cardiomyocytes ; jq ; drug ; abrogated ; phenylephrine-induced genes
Psychosocial Factors ; Heart Failure ; Heart Failure ; Trial ; hz-ACtion
ST2 ; functional capacity ; ambulatory ; hz
EF ; EF ; blinded core
cardiovascular diseases ; heart failure ; hz ; hz
sex ;EF ; bp ; bp ; inhospital mortality
mortalité ; mortalité
DASh ; mortalité ; hz ; Mediterranean
muscle mass ; lean mass
cccka ; polymorphism ; heart failure ; glomerular filtration ; reNASTUR
intubation
Black race ; HF ; modifiable risk factors ; exercise ; HF ; mortalité ; exercise
hearts ; fish ; nucleolin ; developmental impairment ; chamber patterning ; functional deficits ; cardiac looping ; myocyte
fat ; lean mass ; fat ; catabolism ; adipose ; cardioprotective ; hz
drugs ; heart failure ; biomedical reasons ; nonprescribing
hf ; exercise ; respiratory gas
hearts ; ttMena ; mice ; littermates ; heart mass ; transgenic mice
raloxifene ; heart failure
coronary angiography ; systolic HF ; unclear etiology
arterial ; elastance ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ees ; techniques
heart failure ; ventricular ejection fraction ; fes ; exercise ; endothelial ; HFpEF
extracorporeal life support ; bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
HF ; ejection fraction ;HFrEF ; HF ; ejection fraction ; hpEF
angiotensin II ; angleII ; hypoxia ; activateurs ; abnormal ; sCN5a ; mRNA splicing ; sCN5a
rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device ; rhythm
expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs ; rate-control
change ; follow-up ; readmissions ; hospital quality improvement ; follow-up
contractility ; ventricular-arterial coupling ; SV ; ivabradine-treated
puissance spectral ; low-frequency ;high-frequency ;LF ;HF ; CHF-inv ; sham-inv ; sham ; dx

cardiac magnetic resonance ; hf ; biomarker ; hf
myocardial ;DD ; collagen deposition ; obese ; diabetic ; zSF1 ; heart failure ; ejection fraction
hz-ACtion ; left ventricular ejection fraction ; New York ; Heart association ; HF
acute myocardial infarction ; congestive heart failure
pro-B-type natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ; hz
Macrophages ; cardiomyocytes ; Hum-Retn ; mice ; doxorubicin ; hretn ;human resistin ; mRNA ; expression
hz ; immunoreactive ; NT-probNP ; n- ; truncated ; NT-probNP
EH ; HFpEF ; hf ; EF ; hf ; therapy
sympathetic tone ; parasympathetic tone ; heart rate ; metoprolol ; atropine
FM ; plasma ; NPs ; adiponectin ; FM ;f ; changes ; NPs ; adiponectin
lVADs ; CF ; HeartMate II devices ; Thoratec Corp ; Pleasanton ; Calif ; hVAD ; HeartWare intl ; Framingham ; Mass
beat-to-beat ; QT ; eCGs ; atrial pacing ; esmolol ; isoprenaline ; atropine infusion
CAD ; angiography ; systolic HF ; coût
frailty ; Health ABC Short Physical Performance Battery ; hbc Battery ; Gill ; HF
hz ; QRs ; LVf ; ct ; reverse remodeling ; clinical benefit ; LV ; systolic dysfunction
HF ; t2d ;ERC ; treadmill ;VO ; oxygen ; Skm ; biopsies
catheter-based percutaneous revascularization ; angioplasty ; stenting
hospital ; gastrointestinal bleeding ; ventricular tachycardia storm ; heart failure
load-corrected chronotropic response ; heart rate ; exercise ; follow-up ; heart rate ; exercise
cardiac tissue ; mice ;TAC- ; sham-operated ; jq1 ;BET ; inhibition ; pathological cardiac gene expression
epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; abrogate ; pathological gene expression ; hz
cox-proportional hazard models ; negative binomial regression models ; health
heart failure ; noncardiac ; cardiac transplant
Peak oxygen consumption ;VO2 ; HR
NT-probNP ; ed ; acute HF
conditional ; gene-targeted Hand2 ; résistance ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene
Systolic blood pressure ; ventricular ;LV ; hypertrophy ; at ; an ; aas ; mice
rv ; lVAD ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
pf ; New York Heart association ; pf
hf ;AMI ; odds
eds ; responsable ; heart failure ; ed
conditions ; Turkey
Western australie ; administrative health ; hz ;AMI
high-volume physicians ; mortalité ; low-volume physicians ; low-volume hospitals
comanagement ; medication
nursing-sensitive ; science ; treatment ; hz ; nursing
free-breathing pulse ; myocardial ; changes ; swine ; tachycardia-induced heart failure
frail ; Gill ; hz

β-AR ; catecholamine ; infusions ; pde2 expression ; cAMP ; hydrolytic activity ; blunted cardiac ; β-AR
Xanthine oxidase ;XO ; ventricular ;LV ; myocytes ;VO ; mitral regurgitation ; aortocaval fistula ; acf
zf1 ; heart failure ; ejection fraction ; lung ; ventricular ; ejection fraction ; ventricular ;DD
pAH ; acute RV decompensation ; pharmacologic therapies ; RV failure management ; pAH
Chronic heart failure ; chf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
heart failure ; ejection fraction ; hpEF ; health
inhibitor ; jq1 ;BETs ; chromatin ; RNA polymerase ;Pol
ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
intestinal dysfunction ; intestinal barrier ; chronic inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
RA ; methotrexate ; tNF ; non-biological disease ; antirheumatic drug ; nbDMARD
adenosine monophosphate ; cAMP ; guanosine monophosphate ; cgp ; failing hearts
cox proportional hazards regression ; ie ; acute coronary syndromes ; coronary interventions
miRNAs ; RNAs ; expression ; genes ; binding ; RNA ; degradation ; translational repression
catheter ablation ; atrial fibrillation ; af ; heart failure ; preserved ejection fraction ; hf
hf ; ivabradine
mortalité ; healthcare ; management ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
empirically ; heart failure ; hz ; acute myocardial infarction ;AMI ; pneumonia ; pna
pathophysiology ; hf ; medical management ; pathophysiologic
NPs ; heart failure ; pulmonary embolisme ; diabetes ; chemotherapy
Cardiac ; cardiac ; explant-derived cells ; cardiac ; myocardial infarction
sphingosine-1-phosphate receptor ; rs ; β1-adrenergic receptor ; g-protein-coupled ; heart
EF ;LCx ; LAD ; stenting ; infarcted ; ventricle ; LCx ;LAD
signalling cascades ; microRNAs ; expression ; bHLh ; transcription factor ; Hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
BET ; family bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; hz ; HF
cardiac ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
hART ; New York Heart association ;NYHA ; hz ; self-management counseling ; hz
mva ; annular ; implantation ; leaflet motion ; leaflet resection ; edge-to-edge ; anastomosis
EH ; LV ; compliance ; v ; end-diastolic volume ; LV ; end-diastolic pressure ; hg ; coefficient
septal ; pWP
rad ; q66p ; inhibitory actions ; rad ; cav ; cav ; l-type channel ; heart
atrial fibrillation ; carvedilol ; metoprolol
ERC ; DAPc ; sarcomeric microstructure ; Skm ; growth ; myofibre regeneration
grs ; LVf ; CV ; benefit ; clinical ; echocardiographic systolic ; af
cPG-recommended pharmacological treatment ; self-care education ; discharge ; ventricular
Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
Bradycardia ; metoprolol ; cardiac sympathetic tone ; CHF-inv ; rabbits ; sham-inv ; CHF-DNx
blood transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
erythropoiesis-stimulating agent therapy ; benefits ; venous thromboembolisme
voltage-gated ; ventricular action ; excitation-contraction ;EC ; coupling ; myocardium
heart failure ;HF ; tumor necrosis factor ; tf ; tNF ; antagonists ; HF
multivariable logistic analysis ; oxygen uptake ; metabolic exercise ; cardiac ; kidney ; hz
clinical ; genetic ; CHF ; predictive ; curve ; genetic
chronic myocardial ischemia ; stent ; polytetrafluoroethylene
multivariable adjustment ; mortalité ;hazard ratio ; cardiovascular mortality ; hospitalization
Centers for Medicare ; Medicaid services ; cms ; hospital ; mortality ; readmission ; penalties
β-blockade ; disease ; cAMP-dependent protein kinase ; pKA ; β-adrenergic receptor activation
vent ; circulatory failure ; disease ; right heart
hz
grade
aldosterone ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; systolic dysfunction
AT1 ; neprilysin ; blocks renin-angiotens-aldosteron ;RAS ; vasodilatory ; diuretic
bp ; glomerular filtration ; hypertension ; transmitral e-wave ; diastolic mitral annular
ivabradine ; ventricular filling ; heart failure ; preserved ejection fraction ; hpEF
medication ; nonadherence ; salt
HR ; variabilité ; turbulence ; HR ; variabilité ; turbulence ; cardiac
dopamine ; low-dose nesiritide ; renal function ; acute heart failure ; renal dysfunction
hm ; HeartWare ; économique ; hm
glomerular filtration
creatinine ;hazard ; dl ; confidence ; post-transplant mortality
lVAD ; albumin ; hypoalbuminemia ; surgery
pathophysiologique
follow-up ; physician ; discharge ; death ; all-cause ; readmission
CAD ; stenosis ; CAD ; CAD ; descending artery
heart failure ; acute myocardial infarction ; acute myocardial infarction ; Western australie
Randomized aldactone Evaluation ; heart failure ; aldosterone ; spironolactone ; mortalité
annular size reduction ; surgery ; diastolic mitral valve tethering ; leaflet opening ; papillary muscles ; ventricular dilatation
hypertensive ; hf ; sodium-restricted DASh ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
signal transduction cascade ; transcription factors ; pathological changes ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin structure
CHF ; ht ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
ECs ; HDl ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-βII-Ser
ct ; temps ; hf ;hazard ; LVf
heart failure ; histologically ; myocardial collagen ; tissue ; heart failure
administrative ; Alberta ; discharged alive ; hospital ; heart failure
ventricular myocytes ; sarcomere
rcs ; sts ; hz ; hz ; tm ; sts ; tm
PASp ; walking
complications ; implantation ; lVAD ; transplantation ; bt ; dt ; medical therapy
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1PR ; cardiac gene therapy
radial artery tonometry ; PH ; ICU
cardiomyocytes ; pde2 ; cgp ; nitric oxide ; pde2 ; β-AR
ejection fraction ; natriuretic peptide ; heart failure ; inhospital ; Get With the guideline-Heart Failure Registry
Breast cancer ; Medicare coverage ; breast cancer ; chemotherapy ; sEER-Medicare ; Texas Cancer Registry-Medicare
signalosome ; scaffold protein ; kinases ; sequential phosphorylation
magnetically levitated centrifugal-flow ; lVAS
l-dKO ; cardiac ; iRS1 ; iRS2 ; heart failure ; impaired cardiac energy metabolism ; protein kinase
heart failure
hospitals ; heart failure ; hz ; conditions ; acute myocardial infarction ; pneumonia ; conditions
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADt-crte ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
Caloric restriction ; Aerobic Exercise ; Peak oxygen Consumption ; Heart Failure ; Preserved ejection Fraction
ventricular assist devices ; lVADs ; chronic end-stage heart failure ; bridge to transplantation ; bt ; transplant-ineligible ; dt
ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; ventricular ejection fraction
implanted ; interatrial shunt ; haemodynamic ; heart failure ; ejection fraction
RR ; heart failure ; bisphophonates ; crude ;RR ; confidence ; hazard ratio ; hz
acp ; restrictive red blood cell transfusion ; hemoglobin ; hemoglobin ; coronary heart disease
High-cost Medicare ; fee-for-service beneficiaries ; Centers for Medicare ; Medicaid services ; propensity-score
heart failure ; renal dysfunction ; dopamine ; low-dose nesiritide ; renal ; diuretic therapy
réserve ; Rhythm control therapy ; af ; atrial structure ; sinus ; rhythm ; delayed rhythm control ; rate control
kcc ; New York Heart association ; HFpEF ; hf ; EF
nicorandil ; doxorubicin-induced heart failure ; hemodynamic ; mitochondrial dysfunction ; ultrastructural changes ; antitumor activity
physician ; heart failure ; Clinical practice Guideline ; cpg ; heart failure ; hz
hf ; body composition ;skinfold thickness ; dual-energy ; X-ray absorptiometry ; echocardiography ; blood
cardiac ; insulin-resistance ; mitochondrial oxidative metabolism ; metabolic changes ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
économique ; Patient management ; Heart Failure ; coût-effectiveness Model ; long-term cost-effectiveness ; disease management ; heart failure
rad ; rGK ; rem ; rem2 ; rad ; Gem ;Kir ; monomeric g proteins ; ventricular action ; EC ; coupling gain ; cardiac
breathing control ; cardiac arrest ; pulseless ventricular fibrillation ;PVf ; implanted ; cardioverter-defibrillator device
annular size reduction ; surgery ; diastolic mitral valve tethering ; leaflet opening ; papillary muscles ; ventricular ;LV ; dilatation
pathophysiology ; heart failure ; preserved ejection fraction ; hf ; myocardial extracellular matrix accumulation
cox model ; PASp ; exercise ;hazard ; PASp
Oral glucocorticoids ; hz
HFPSI ; medical hospitalization ; HF ; clinic outpatients ; HF ; health systems
HR ; ivabradine ; Ea ; TAC
guidelines-Heart Failure ; hf ;EF ; EF
VO2 ; change ; lean body mass ; change ; thigh ; muscle ; intermuscular fat
testosterone ; rehabilitation ; health ; CHF ; testosterone
chm ; adjunctive treatment ; dm ; heart failure
carvedilol ; metoprolol ;hazard
acetylcholinesterase ; pyridostigmine ; sympathovagal balance ; cardiac remodeling ; hz ; myocardial infarction
re-hospitalization ; admissions
financiers ; cardiac arrest ; cardiopulmonary resuscitation ; cp ; posterior wall infarction ; cardiac
heart failure ;HF ; ejection fraction ;rEF ; renin-angiotensin system ;RAS ; β-blockers ; mortalité ; readmissions
uPR ; sCN5a ; ventricular systolic ; hz ; induced pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; insulin
acp ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
hyperkalemia ; mineralocorticoid receptor antagonists ; mineralocorruption receptor antagonists ; heart failure ; hz
pde superfamily ; pde2 ; cgp ; cAMP hydrolysis ; cross talk ; cgp ; cAMP
mitochondrial-targeted antioxidant ; Szeto-Schiller ;SS ; SS20 ; cardiac function ; proteomic remodeling
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; β-blocker
tAPse ; longitudinal RV ; fiber shortening ; PASp ;force ; RV ; in vivo ; RV ; length-force
coprimary ; urine ; decongestion ; change ; cystatin c ; enrollment ;renal function
brain natriuretic peptide ; bp ; bp ; bp ; bp
LVEF ; reverse remodeling ; temps ; hz ;hazard
Swedish Web-system for enhancement ; evidence-based care ; Heart disease ; Recommended Therapies ; cag ; stockholm
proBp ;NT-probp ; proANp ; m-proanp ; adiponectin ; CHF ; bmi ; FM
MI ; vent ; hz
carvedilol ; Willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
EC ; HDl ;NYha-IIIb ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDl
HF ; EF ; HF ; EF ; change ; HF ; MI
ctnt ; NT-probNP ; aRIC HF ; acs ; NRs
cardiovascular events ; sST2 ; metoprolol succinate
Medicare ; acute care hospital ; hz ;AMI ; pna
décision-support ; financial incentives ; cochrane Effective practice ; organisation of Care ; Taxonomy
mouse ; heart failure ;HF ; hypertensive heart disease ; hd ; pathophysiology ; hd
coup ; CHF ; cf ; icc ; kappa
ventricular longitudinal systolic strain ; grs ; ventricular mechanics ; cardiovascular ;CV ; atrial fibrillation ; af
implantable cardioverter-defibrillator deactivation ; distressing ; implantable cardioverter-defibrillator
heart failure ; myocardial function ; ventricles
implantable ; cardioverter-defibrillator deactivation ; implant ; change ; end-of-life
heart failure ; left ventricular ejection ; aerobic ; dynamic resistance ; lower limbs
mouse ; rad ; murine ; rad ; currents ; cav ; cav ; rad
ct ; hazard ; confidence
fit ; unfit ; cRF ; fit ; unfit ; body mass ; obese
ventricular ; ejection fraction ; egFR
coût ; rhythm-control ; rate-control
prescribing ; guideline-recommended medications ; medical records
ethically complex situations ; pediatrics ; religious beliefs ; life-sustaining treatment ; legal majority ; décision ; life-sustaining treatment
Medicare ; Patient Safety Monitoring system ; mps ; adverse event ; acute myocardial infarction ; congestive heart failure ; pneumonia ; conditions ; surgery
sarcoplasmic reticular ;SR ; protein ; SR ;pump ; phospholamban ; infarcted hearts ; metoprolol
hfPSI ; blood ue nitrogen ; natriuretic peptide ; New York Heart association ; diabetes ; atrial fibrillation ;flutter
Timed up & Go ; tue ; chronic obstructive pulmonary disease ; cp ; chronic heart failure ; chf ; renal failure ; crf
RM ; home telemonitoring ; tm ; implanted monitoring devices ; medical support ; sts ; contact ; hz ; hz
heart failure ;HF ; plasma ; b-type natriuretic peptide ; bn ; ejection fraction ;EF ; HF ; sex
grs ; left ventricular ejection fraction ;LVf ; systolic mitral annulus ; CV
hf ; LVf ; long-term mortality ; LVEF ; LVf ; long-term mortality
intramuscular testosterone ; heart failure ; chf ; testosterone
cox regression ; beta-blockers ; beta-blockers ; inappropriate therapy ; antitachycardia pacing ; acp ; shock therapy
rehabilitation ; walking ; Minnesota ; quality of life
congestive heart failure ; ed ; fréquence coefficient
angiotensin-converting enzyme inhibiteurs ;angiotensin receptor blockers ; β-blockers ; heart failure ; ejection fraction
Rats ; hearts ; caspase-3 activity ; phosphocreatine ; adenine nucleotides ; cytochrome ; bcl2 ; Bax ; caspase ; expression
ventricular pacing ; Bax ; bcl-2 ; Caspase-3 ; rte-PCr ; interventricular septum biopsies ; beagle ; heart failure
sodium-restricted dietary ; hypertension ;DAS ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive ; hf
medication ; physical therapy ; implantable defibrillateurs ; circulatory support ; transplantation ; heart failure
CD34 ; génér2 ; functional capacity ; figure ; VO2
arginine ; vasopressin ; aVP ; physiologic processes ; CHF ; aVP ; vasopressin receptor antagonist ; therapy ; CHF
heart failure ; reduced ejection fraction
aerobic ; resistance ; benefits ; exercise capacity ; muscle strength ; cardiac ;NT-ProbNP ; inflammatory ; i6 ; hsCRp ; biomarkers
reversibility ; heart failure ; myocardial infarction ; m ; β-adrenoceptor blockade ; infarcted ; metoprolol
tension ; fréquence ; muscle ; kv-KI ; treatment ; titin ; extracellular matrix ; Fpassive
CHF ; anthracycline ; stem cell
case-fatality ; HF ; HF ; case-fatality
hospital ; readmission ; all-cause readmission ; acr ; Potential Preventable Readmission ; pd ; Centers for Medicare ; Medicaid ; cm
metoprolol ; carvedilol ; sympathetic activity ; Willebrand factor ; graphe ; grly
acute HF ; RELAx-aHF ;ASTRONAUT ; prONTO ; patient enrollment
Hospitalized ; hf ; international Classification of Diseases ; Clinical Modification ; codes ; principal ; discharge
Pulmonary capillary wedge ; pressure ; hg ; hg ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
rad ; Q65p ; mouvement ; rad ; Q65p ; impair ; l-type channel ; inhibition ; GK ; proteins
SS20 ; heart failure ; proteomics changes ; actin cytoskeleton ; SS20 ; mitochondrial ; metabolic
New-onset ; aortic insufficiency ;AI ; mechanical circulatory support ; flow ;CF ; ventricular assist devices ; lVADs ; pulsatile devices
pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; ventricular dysfunction ; hz
discharge ; follow-up
life expectancy ; heart failure ; heart failure
heart failure discharges ; University of Connecticut Health Center ; follow-up
New York ; Heart association ;NYha ; Heart Failure ; eplerenone ; Heart Failure Medicines ;EMPhaSIS-HF
ventricular base ; midpapillary ; IVc ; BiVP ; ste ; twist ; apical ; basal rotations ; cs ; RS
drugs ; RAas ; direct renin ; inhibiteurs ; endopeptidase ; inhibiteurs ; vasopeptidase ; inhibiteurs ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic ; calcium-sensitizing agents ; endothelin ; vasopressin ; adenosine
hf ; mice ; phenylephrine ; haemodynamic stress ; transverse aortic constriction ;TAC ; jq1 ; pathological changes ; cardiac hypertrophy
Muscle aerobic capacity ; postexercise ; phosphocreatine resynthesis ; Fontan
i-miBG ; cardiac washout ; carvedilol ; metoprolol ; β2-adrenergic receptor haplotype
acute myocardial infarction ;AMI ; heart failure ; hz ; complicating ; am
h-dKO ; ventricular mass ; cardiac apoptosis ; fibrosis ; Akt ; forkhead box ; impaired cardiac metabolic gene expression ; ATP
bottleneck ; stent ; implanted ; proximal left anterior descending ;LAD ; proximal circumflex artery ;LCx ;LCx ;LAD ; pigs
vent failure ; hf ; dipeptidyl peptidase-4 ; dp-4 ; antihyperglycemic agents
quality improvement ; multivariable cox modeling ; Heart Failure ; Patient Severity index ; hzPSI ; University of Michigan ; hz ; ue ; om
pde2 ; overexpression ; cardiomyocytes ; cAMP ; ca2 ; amplitude ; inotropic effect ; β-AR ; basal contractility
ATP ; shock therapy
Cardiac resynchronization therapy ; ct ; dialysis-dependent ; heart failure ; hz ; ct ; dialysis
joint ; cardiorespiratory fitness ; crf ; body mass index ; heart failure ; hz ; mortality ; cardiovascular risk factors ; HF ; mortality ; fit
eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone ; Mild Patients ; hospitalisation ; survIval Study in Heart Failure
Heart ; hz ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ; chf ; left ventricular ;LV
neonatal rat ; ventricular cardiomyocytes ; insulin ; iRS1 ; iRS2 ; insulin action ; cardiac dysfunction ; insulin resistance ; diabetes
ventricular midpapillary ; atrioventricular delay ; avd ; interventricular delay ; vd ; ste ; circumferential strain ; cs ; radial strain ;RS
New York Heart association ;NYha ; functional class III ; hz ; ejection fractions ; chronic ; guideline-directed medical therapy ; dt ; United States ; Canada ; europe
abb ; QRs ; ms ; ms
dyssynchronous ;HF ; myofiber ; septum ; myofiber ; stretch ; lateral
label-free shotgun ; proteomics ; proteomics ; changes ; transverse aortic constriction ;TAC ; heart failure ; changes
CHF ; transforming growth factor ; tf ; epithelial ; mesenchymal transition ; pluripotency ; shams
pka ; change ; regulatory ;RI ; expression ; rII ;Ser ; phosphorylation ; hz
hf ; left ventricular ejection fraction ; hf ; left ventricular ejection fraction ;RAS ; β-blocker ; dose changes ; hf
g-protein-coupled receptors ; physiological significance ; hearts ; β-adrenergic receptor ; rat ; postischemic heart failure
concentric remodeling ; cr ; concentric hypertrophy ; ventricular ;LV ; remodeling ; heart failure ; preserved ejection fraction ; hpEF ; eccentric hypertrophy ; ed
weight ; exercise ; dt ; exercise ; diet
RV dysfunction ; confidence ; cachexia
venting ; HR ; VO2 ; resting HR
tf-β ; c-Kit ; cell ; cardiac progenitor ; cell expansion
NT-Probp ; inflammatory biomarkers ; hscrp ; IL ; hscrp
BETs ; neurohormonally induced heart disease ; nanomolar ; jq ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
BAT ; pro-brain natriuretic peptide ; heart failure ; GDt ; NYha ; class III HF
p70 ; PKc-βII ; HDl ; jha-IIIb ; malondialdehyde ; HDl ;NYha-IIIb ; HDl
mlf ; diet ; exercise ; diet
nonpace ; non-DNx ;ham-Innervated ;ham- inv ; pde ; hz-DNx ; pace non-DNx ; chf- inv ; pace ; DNx ; chf-DNx
hz ; batterie ; HF ; Health ; ABC ; hz ; SD ; death
ejection fraction ; frail ; biological phenotype ; death ; frailty
hemoglobin ; hgb ; HRQol ; training-induced changes ; HRQol ; Heart Failure ; controlled Trial Investigation ; hz-ACtion
atrial Fibrillation ; congestive Heart Failure ; health ; expenditures ; Québec ; rhythm ; rate-control ; treatment ; single-payer ; coût-minimization
heart failure ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; renal dysfunction
calcineurin ;fat ; mir-25 expression ; helix-loop-helix ; bHLh ; transcription factor ; Hand ; myocardium
Exercise ; PSs ; btes ; exercise ; PSs ; btes
NT-probNP ; sensitivity ; confidence
puissance ; r-r ; HR ; fractal scaling
diastolic filling formalism ; relaxation ;viscoelastic ; passive ;stiffness ; doppler ; mitral inflow ; e-wave
heart failure ;HF ; ventricular tachycardia ;HF ; hz ; VT ; hz
grs ; cox model ; chronic heart failure ; hypertension ; diabetes ; stroke ; glomerular filtration ; LVf ; benefit ; CV
VAD ; ventricular assist device ; ECmo ; extracorporeal membrane ; oxygenation membrane ; ECmo ; VAD
ischemic events ;IEs ; ischemic cardiomyopathy ; icc ; cardiac resynchronization ; therapy ; defibrillator ; ct-d
coût-effective ; heart failure ; disease management ; treatments ; health care system
resistin ; heart failure ; mouse ; murine ; resistin ; transgenic ; Retn gene ; hum-retn ; mice ; inflammation-stimulated
angiotensin-converting enzyme inhibiteurs ;angiotensin receptors ; blockers ; β-blockers
tt ; figure ; cardiac injury ; ejection ; fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
resynchronization-Defibrillation ; Ambulatory Heart Failure ; implantable cardioverter ; defibrillator-ct ; mortalité ; heart failure
heart failure ; allemagne ; confirmatory factor analysis ; cf ;SCHf ;Sel-Care Maintenance ; Self-Care management ; Self-care Confidence
mwt ; NYha ; HFpEF ; hf ; therapy ; HFpEF ; death ; HF
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; ventricular ejection fraction ; iCD ; mortalité ; ischemic cardiomyopathy
Raf-MEK1/2-ERk ; scaffold proteins ; cardiac remodelling
CHF ; SD ; testosterone ; exercise ; testosterone
ms ; LV ; dilatation ; heart failure ; hz ; LV ; functional ms ; hz ; MR ; degenerative mitral valve
New York Heart association ; kccq ; fréquence ; aNOVA ; HF ; EF ; HFpEF
angiotensin converting enzyme inhibitor ; angion-receptor ; blockers ; β-blockers ; heart failure ; medications ; medical records
c57BL ; ANG ; ANG ; infusion ; uninephrectomy ; ANG ; infusion ; salt loading ; ANG ; infusion ; uninephrectomy ; salt loading
early transmitral blood flow ; doppler ; early diastolic mitral annulus ; pulmonary capillary wedge pressure ; pdp ; systolic heart failure ; hz
ejection fraction ; strain ; systole ; diastolic ; strain ; diastole ; early transmitral flow ; sinus rhythm
VO2 ; exercise ; body mass ; diet ; masse
age- ; sex-adjusted ; hazard ; confidence ; early-onset ; hz ; late-onset ; hz
AMI ; hospital ; Hospital ; dying
Mass spectrometry ; NT-probNP ; physiological proteolysis ; pro2- leu3 ; leu3-g ; pro6-g76
sex-specific ; ctnt ; NT-probNP ; ctnt ; NT-probNP ; HF
HFpEF ; New York Heart association ; mean ejection fraction ; fees
depressed left ventricular ;LV ; systolic pressure ; pressure ; ejection fraction ; fractional shortening ; cardiac output ; LV ; end-diastolic pressure ; MI ; metoprolol
Barreflex Activation Therapy ; Heart Failure ; Reduced ejection Fraction ; carotid ; baroreflex activation therapy ;BAT ; heart failure ;HF
enrollment
hf ; blood glucose ; obesité ; tobacco ; aging ; systemic hypertension ;SH ; rheumatic fever ; Chagas ; disease ; cd ; la
cf ; overweight ; obese ; body mass
kccq ; HFpEF ;log ; EF
edf ; edf ; edf ; hypertension ; diuretics ; temps ; ESRD
myocardial phosphodiesterase-2 ; pde ; heart failure ; hz ; pde ; beta-adrenergic receptor ;β-AR ; cardiomyocytes
heart failure ; cardiac resynchronization ; defibrillator ; implantable ; cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
ERC ; epicatechin-rich cocoa ; Skm ; mitochondrial structure ; rob ; ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; maisel ; Henry
urgent readmission
Mena overexpression ; TTA ; mice ;TAC ; surgery ; cardiac hypertrophy ; TTA ; TAC ; cardiac functional deterioration
echocardiography ; LV ; end-diastolic ; MR ; mitral valve ; mva ; pressure ; hg
p ; diuretic refractory severe-end-stage ; hf ; prelated complications
ATP ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium ; hyperkalemia ; medication
New York ; Heart association ; heart failure ; hz ; ventricular ejection ; permanent periodic breathing ; p
implantation ; bottleneck ; stent ; proximal LAD ;LCx ; reversible myocardial ischemia ;open stent ; ischemic heart failure ; stent
potassium ; spironolactone ; AAs ; AAs
obese ;SD ; body mass ; hf
proangiogenic effects ; b ; VEGF pathway ; adenoviral vector ; decoy ; VEGF receptor ; ad-flk ; adenovirus ; ad-c
surgery ; post- lVAD ; aortic valve ; leaflet ; repair ; bioprosthetic ; aortic valve replacement ; CF ; lVAD ; AI
exercise-induced pulmonary ; artery systolic pressure ;PAS ; stress ; doppler echocardiography ; ventricular contractile ; pulmonary hypertension ; heart failure
MEDline ; eEMBAse ; HEalthSTAR ; cINAHL ; cochrane Library ; Campbell Collaboration ; Joanna Briggs Institute ; evidence Based practice ; Centre for Reviews and Dissemination ; evidence Based practice
VA ; healthcare systems ; systolic heart failure ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor ; blocker
heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibiteurs ;angiotensin receptor blockers ; angiotensin converting enzyme inhibiteurs intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
open chest model ; twist ; RS ; RS synchrony ; cste ; changes ; co ; rvpo ; changes ; RS synchrony ; c ; BiVP ; co
tAPse ; PASp ; graphe-to-PASp ; figure ; cox regression ; Kaplan-meier ; tAPse ; PAS
cPET ; CHF ; exercise ; exercise ; rehabilitation
heart failure ;HF ; mRNA splicing ; v ; voltage-gated cardiac ; nations ; cn5a ; truncated ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; cellular responses ; heart failure ; anthracycline ; malignant disease
économique ; Patient management ; Heart Failure ; Cost-effectiveness Model ; medications ; costs
natriuretic peptides ;NPs ; b-type NP ; pro-B-type NP ; acute heart failure ; Emergency Department ; ed ; acute dyspnea
oxygen ; VO2 ;ven ; vco2 ; ventilation ; eOV ; pressure ; end-tidal CO2 ;PETco ; cardiopulmonary exercise
Denmark ; bisphosphonates ; raloxifene
hypertension ; LV ; dilatation ; LV ; dysfunction ; MR ; ms ; mitral valve ; closure ; organic lesion ; systolic ; diastolic tethering ; functional etiology ; MR ; ms
tolvaptan ; hyponatremia ; United States ; japon ; congestive heart failure ; diuretic therapy ; serum sodium ; systolic
longitudinal strain ; left ventricle ; echocardiographic ; echocardiography ; ct ; echocardiograms
platelet-activating factor ; pf ; metabolic enzymes ; heart failure ; hz ; bmi
acute care surgery ; acs ; consultations ; ot ; transplantation ; medical therapy ; m ; intravenous inotropes ; ventricular assist devices ;VADs
HFpf ; ivabradine ; exercise ; ventricular ; filling pressure ; exercise ; early diastolic mitral flow ; diastolic mitral annular velocity
renin-angiotensin-aldosterone system ; aas ; hf ; angiotensin-converting enzyme ; angiotensin receptor blockers ; aldosterone ; HFpEF
lVET ; tonometric indices
heart ; blood pressure ; renal function ; spironolactone ; RAS ; blockers ; β-blockers
cardiac performance ; β-adrenoceptor blockade ; heart failure ; SR ; ca(2+)-pump ; reverse cardiac remodeling ; plasma catecholamines
angiotensin-converting enzyme inhibiteurs ;angiotensin receptor blockers ; β-blockers
SS31 ; congestive heart failure ; mitochondrial damage ;TAC ; mitochondrial proteome changes ; mitochondrial ; nonmitochondrial protein changes
myofibrillar ; ATPase activity ; mRNA ; pump ; phospholamban ; α-myosin heavy chain ; mRNA ; β-myosin heavy chain ; metoprolol
HDl ;HD ;healthy ; CHF-NYHA-III ;HD ;NYha-III ; et ; CHF-NYHA-II ;HD ;NYHA-II
anesthetized dogs ; coronary microembolisation-induced ; hz ; cXL-1020 ; ventricular end-diastolic pressure ; myocardial oxygen ; ejection ; ventricular puissance
md ; confidence ; mdp ; mdp ; confidence ; mdp
heart failure ; administration of contrast ; ms ; administration ; ms
HF ; la ; idiopathic dilated cardiomyopathy ; cd ; ischemic ; SH ; valvular ; alcohol
ST2 ; functional capacity ; ambulatory patients ; HF ; Heart Failure ; controlled Trial Investigation Outcomes ; Exerci Training ; HF-ACtion ; exercise ; HF
cardiopulmonary exercise ; exercise rehabilitation ; patients ; chronic heart failure ; heart failure ; chf ; cards ; corruption ; cpe ; exercise rehabilitation ; france
AA ; ischemic HF ; NYha ; functional class IV ; glomerular filtration ; heart ; hypertension ; diabetes mellitus ; myocardial infarction ; AA
hf-ACtion ; ventricular ejection ; HRQol ; Kansas City ; Cardiomyopathy Questionnaire ; kcc
ct ; systolic dysfunction ; resynchronization reverses ; remodeling ; Systolic left ; entricular dysfunction ; ventricular ;LV ; ejection fraction ;LVf
glomerular filtration ; edf ; diabetes ; cholesterol ; lDL-cholesterol ; CLnKA ; GG
echocardiography ; end-diastolic ; LV ; end-diastolic ; pressure ;wall stress ; lung weight ; acf ; sham
aUC ; aUC
spironolactone ; hospitalisation ; death
Rate-control ; cardiac procedures ; cardioversions ; costs ; antiarrhythmic drugs ; confidence interval
diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme ; angiotensin II receptor blocker
eplerenone ; post myocardial infarction ; Heart failure Efficacy ; survival Study ; eweSUS ; post-myocardial infarction ; heart failure ; mortalité ; aldosterone antagonist eplerenone
carvedilol ; metoprolol ; implantable ; cardioverter-defibrillator therapy ; MAD-ct ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
risk reduction ; hz ; confidence ; heart failure-related mortality ; sudden death ; HR
DASh ; RD ; brachial systolic pressure ; hg ; central end-systolic pressure ; hg
hf ; obese ; body mass ; black ethnicity ; idiopathic-dilated cardiomyopathy
mortalité ;HF ; LVf ; Heart Failure Survey ; ISrael
ventricular ejection fraction ; World Health Organization ; idiopathic dilated cardiomyopathy ; coronary angiography
european Society of Cardiology ; hff ; heart failure ; ejection ; left ventricle ; diastolic dysfunction ; relaxation ; LV ; diastolic stiffness ; LV ; filling pressures
β1ARs ; s1PR1s ; myocyte ; action ; cAMP ; regulatory ; g-protein-coupled receptor kinase-2
PAf-cp ; PAf ; lyso-paf-AT ; PAf-AH ; lp-PLA2
heart failure ; ejection fraction ; cardiac rehabilitation ; Nordic walking
ds-stratified hazard ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
skeletal ; muscle mass ; t-score ; sarcopenic range ; muscle ; wasting ; t-score
testosterone ; oxygen uptake ; Beck ; depression inventory ; leg strength ; Medical Outcomes ; Short-Form quality of life
RAS ; β-blocker ; mortality ; hf ; hf ;hazard ratio ; confidence
Heart Failure ; controlled Trial Investigating Outcomes ; exercise Training ; hz-ACtion ; social support ; social support ; ps ; barriers ; exercise ; btes
ST2 ; cardiovascular death ; hz ; mortalité ; hazard
New York Heart association ; cardiopulmonary exercise ; lean mass ; x-ray absorptiometry ; dXA ; calf ; muscle ; magnetic resonance spectroscopy
dopamine ; low-dose nesiritide ; diuretic therapy ; renal function ; acute heart failure ; renal dysfunction
ct ; New York Heart association ; heart failure ; left ventricular ejection ; QRs ; echocardiographic ; left ventricular dyssynchrony
ventricular ;LV ; ejection ; hf ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow ; mitral annulus ; diastole
acute coronary syndromes ; CAD ; bNP ; NT-probNP ; CAD
hf ; lyso-paf-AT ; PAf-cp ; PAf ; PAf-AH ; lp-PLA2
sternotomy ; aortic valve ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve ; transcatheter ; aortic valve ; open surgery ; aortic valve replacement
n-terminal pro-B-type natriuretic peptide ;NT-probNP ; acute heart failure ; hz ; emergency department ; ed
cardiac troponin ; ctnt ; high-sensitivity ; pro-B-type natriuretic peptide ;NT-probNP ; biomarkers ; hz ; hz ; Atherosclerosis Risk in communautés ;ARIc
body mass ; hz ; fat mass ; fat-free mass
body mass ; pd ; CHF ; cf
reverse remodeling ; ejection fraction ; mortalité ; hz ; dialysis
EH ; LV ; contractility ; LVf ; coefficient ; confidence ; systolic blood pressure ; end-systolic ; hg
echocardiography ; LV ; end-diastolic volume ; LV ; ejection ; MR ; mitral valve opening ; ms ; mva ; pressure
clinical trial ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration
BETs ; chromatin-mediated signal transduction ; Pol II ; transcription factor ; réseaus ; hz ; nucléaire factor ; activated T cells ; nFAT ; nucléaire factor-κb ;NF-κb ; transcription factor ; gATA4
mortalité ; cardiovascular events ; myocardial infarction ; congestive heart failure ; exacerbation ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
all-cause ; cardiovascular mortality ; multivariable adjustment ; hazard
EO-cfus ; diabetes ; diabetes ; e-cfu ; VO2 ; diabetes ; EO-cFUs ; VO2
immunoblotting ; radioenzymatic- ; fluorescence ; resonance ; energy transfer-based ; edge ; epifluorescence microscopy ; ca2 ; myocardial tissues ; cardiomyocytes ; hz
eas ; atrial fibrillation ; Stroe prevention ; af ; stroke ;CHA2DS2VASc ; rhythm control therapy
Exercise capacity ; oxygen consumption ;VO ; Qol ; Minnesota Living with Heart Failure ; mlf ; Questionnaire ; heart failure ; Qol
TAC-induced proteomic ; mitochondrial-targeted peptide ; SS31 ; mitochondrial function ; TAC ; mitochondrial-targeted peptide ; heart failure
ventricular ejection fraction ;HF ; preserved ; left ventricular ejection fraction ; hospital ; physicians ; acute ; outpatients ; management ; financiers
hf ; ventricular ;LV ; ejection fraction ; hf ; echo-doppler ; pro-brain-type natriuretic peptide
eds ; hospitalized ; odds ; eds ; aOR
cardiac transplant ; ECCT ; diabetes mellitus ; chronic kidney disease ; glomerular filtration
habb ; Battery ; Health ; ABC ; HF Risk Model ; discrimination ; c-index ;net-reclassification-improvement ; HF
cf ; RMse ; Self-Care Maintenance Scale ; cf ; RMse ; Self-Care management Scale ; cf ; RMse ; Self-care confidence
BAT ; quality-of-life ; NYha ; functional class ranking ; change
preoperative hypoalbuminemia ; albumin ; hypoalbuminemia ; albumin ; lVAD
rehospitalization ; acute myocardial infarction ;AMI ; complications ; kidney infection ; urinary tract infection ;UTI
patients ; heart failure ;HF ; ischemic ; cardiomyopathies ; pharmacological armamentarium ; implantable ; cardioverter defibrillateurs ; cardiac resynchronization therapy ; cardiac transplantation ; ventricular assist devices
SAF ; pf ; catheterization ; central venous pressure ; hg ; rv ; dyn ; cardiac
admission ; median bp ; EF ; EF ;median bNP ; EF
heart failure ; heart transplantation ;LV ; assist device ; death ; death
ejection fraction ; circumferential shortening ; systolic elastance ; contractile efficiency ; aCF ; aCF ; allopurinol ; rats ; o2 ; cardiomyocytes ; extracellular flux
HFpEF ; LV ; normal geometry ; LV ; hypertrophy ;LV ; wall thickness ;RW ; cr ; LVh ; WT ; vh ; WT ; EH ;LVh ; WT
lCZ ; angiotensin receptor ; neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist ; valsartan ; hypertension ; heart failure ; ejection fraction ; heart failure ; ejection fraction
blood pressure ; mitral valve ; plasty ; degenerative MR ; prolapse ; chordal ruptures ; triangular resection ; edge-to-edge ; anastomosis ; ring annuloplasty ; Physio Ring ; edwards Lifesciences ; irvine
shuttle walk ; oxygen uptake ; muscular strength ; echocardiographic ; pro-brain natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ; minnesota Living ; Heart Failure ; Medical
LVEF ; long-term mortality ; LVEF ; age-by-LVEF
Wistar-Kyoto ; lean ; zs1 ; obese ; zs1 ; high-fat ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
Kaplan-meier ; log-rank ; risk stratification ; UM ;va ;va-RT ; UM
multivariate cox regression ; af ; af ; hypertension ; sinus rhythm ; hz ; confidence
HF-ref ; NYha ; functional class II ; egFR ; potassium ; eplerenone ; hyperkalemia ; wf
fréquence ;f ; FM ; body fat distribution ; dual energy ; X-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ; chf ;cc ; non-cachectic CHF ; myocardial infarction-both
drug ; spironolactone ; death ; hz ; AAs ; AAs
pulmonary arterial hypertension ; thromboembolic pulmonary hypertension ; ventricular pump ; pulmonary arterial hypertension ; medication ; stress ; echocardiography ; cardiopulmonary exercise
cardiovascular death ; hz ; btes ; btes ; cardiovascular death ; hz ; figure ; fréquence
CAD ; diabetes ; electrocardiographic ; waves ; bundle branch block ; nondiabetes ; risk factors ; dyslipidemia ; hypertension ; tobacco
ed ; ed ; readmission ; aOR ; eds ; aOR
implantable cardioverter-defibrillator deactivation ; implantation ; implantation ; implantable cardioverter-defibrillator deactivation
Cardiac magnetic resonance ; atrial ; pulmonary vascular resistance ; cardiac
hf ; systolic ; ventricular ejection fraction ; HF ; conditions ; New York Heart association ; echocardiographic ; cardiopulmonary exercise
heart failure ; ABCd ; American College of Cardiology ; accc ;American Heart association ;AHA ; New York Heart association ;NYHA ; structural heart disease ; heart failure
mva ; continuity ;LV ; end-diastolic ; end-systolic ; mitral filling flow ; mva ; temps ; mitral filling ; wave ; doppler echocardiography ; MR ; mitral valve ; plasty
statitistical significance ; RM ; all-cause mortality ; sts ; hz ; cr ; TM ; cri ; TM ; Cr
HFPSI ; Ann Arbor ; Veterans Affairs ; hf ;va ; HFPSI ;va-RT ; VA ; HFPSI
hf ; diuretics ; co-morbidités ; mwt ; NYha
HF ; postoperative ; echocardiography ; LV ; end-diastolic volume ; LV ; ejection ; MR ; mitral valve opening ; mitral valve ; mva ; pressure ; hg
AAs ; non-AAs ; spironolactone ; hyperkalemia ; puissance ; hypokalemia ; puissance
LVEF ; long-term mortality ; LVEF ;hazard ratio ; LVEF ; LVEF
HFpEF ; NYHA ; walk ; mwt ; medications
pulmonary ; arterial systolic pressure ;PAS ; right ventricular ;RV ; tricuspid annular plane systolic excursion ; rte ; diastole ; end-systole ; heart failure ; hz ; cardiac
reverse remodeling ; ct ; ventricle ; left ; atrial ; ventricular ; end-diastolic ; ventricular ; change
receiver ; operating characteristic curve ; ac ; pib ; confidence ;septal ; ewean
iRS1 ; iRS2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS1 ; iRS2 ; heart-specific ; iRS1 ; géné double-knockout ; h-dKO ; liver-specific ; iRS1 ; iRS2 double-knockout ; l-dKO
b-type natriuretic peptide ; pro-B-type natriuretic peptide ; coronary artery disease ; bp ; bp ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
trastuzumab-treated ; coronary artery disease ; hypertension ; trastuzumab ; administration ; CHF
LVf ; clinical composite response ; ct ; ct ; LV ; systolic volume ; LV ; mass
tf-β ; tf-β ; smemad ; small-molecule inhibiteurs ; c-Kit ; cell yield ; epithelial ; mesenchymal transition ; pluripotency marker ; nanog ; c-Kit ; cell ; cardiomyocyte
systolic heart failure ; ivabradine ; SHIFT ;Systolic Heart Failure ; treatment ; If inhibitor ivabradine Trial ; ivabradine ; echocardiographic
liberal transfusion ; mortalité ; mortalité ; i2 ; mortalité ; acute coronary syndrome
readmission ; physician ; hazard ratio ; hz ; confidence ; physician ; hz ; follow-up ; follow-up
pde ; hz ; pde ; New York Heart association ; functional class
hz ;human embryonic kidney ; figures ; s1PR1 ; downregulation ; sphingosine-1-phosphate ; S1PR1 ; downregulation ; isoproterenol ; β-adrenergic receptor agonist
cansas City ; Cardiomyopathy ; Minnesota ; Heart Failure ; depressive ; beck ; depression ; corruption ; depression ; natriuretic peptide ; endothelial ; ventricular diastolic
Renal function ; Chronic Kidney Disease Epidemiology ; glomerular filtration rate ; edf
prospective ; multicenter trial ; PARADIGm-HF ; chronic heart failure ; systolic dysfunction ; vf ; functional class ; NYHA ; bp ; bp ;cardiovascular death ; heart failure ; ARNI ; lz ; sacubiltril ; valsartan
hyperkalemia ; afriques ; as ; as ; New York Heart association ;NYha ; hz ; ventricular dysfunction ; spironolactone ; Randomized aldactone Evaluation Study ;RALes
cardiovascular events ; atrial fibrillation ; ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration ; acute kidney injury
diastolic function ; ventricular-arterial coupling
disease risk score ; ds ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
IE ; revascularization ; coronary artery ; bypass ; surgery ; percutaneous coronary intervention ; systolic blood pressure ; hz ; electrocardiogram ; IE
biomedical treatment ; biomedical treatment ; chm ; ventricular ejection ; ventricular diastolic end diameter
open-label crossover ; heart failure ; ventricular ejection ; fraction ; Arg16 ; grt27 ; gly ; corruption ; β2-receptor ; carvedilol ; metoprolol
prescription ; angiotensin-converting enzyme ; inhibiteurs ;angiotensin receptor blockers ; β-blockers
Therapy ; ivabradine ; change ; exertional ; diastolic mitral flow ; early diastolic mitral annular velocity ; exercise ; therapy ; ivabradine ; oxygen uptake
PAf ; biosynthetic enzymes ;lyso-paf acetyltransferase ;lyso-paf-AT ; dithiothreitol ; dt ; CDp ; choline ; 1-alkyl-2-acetyl-sn-glycerol ; cholinephosphotransferase ; pf-cp ; catabolic isoenzymes ; PAf-acetylhydrolase ; pf-AH ; lipoprotein-associated phospholipase a2 ; lp-PLA2 ; leukocytes
low-volume ; ed ;hospitalisation ; ed ; aOR ; aOR ; high-volume ; ed ; aOR ; aOR
ivabradine ; follow-up ; exercise capacity ;METs ; oxygen uptake ; exercise-induced ; early diastolic mitral flow ; early diastolic mitral annular
Health Buddy ; risk-adjusted all-cause mortality ;hazard ratio ; hz ; confidence ; inpatient admissions
multivariable-adjusted hazard ; Mediterranean ; diet score ; DASh
ctnt ; NT-probNP ;laboratory report ; aRIC ; hz ; systolic blood pressure ; antihypertensive ; medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart ; hz ; receiver ; operating characteristic curve ; ac ; discrimination ; reclassification ; nRI
eplerenone ; hyperkalemia ; renal function ; wf ; EMPHASIS-HF ; heart failure ; ejection fraction ; hz-ref ; New York Heart association ;NYHA ; glomerular filtration ; egf ; serum potassium
NYha ; class II ; change ; Duke ; activity Status index ; dp ; Kansas City ; Cardiomyopathy Questionnaire ; dp ; walk
low-dose ; dopamine ; cumulative urine ;dopamine ; change ; cystatin c ;dopamine
nesiritide ; cumulative urine ;nesiritide ; change ; cystatin c ;nesiritide
Nordic walking ; functional capacity ; mwt ; physical activity ; right grip ; depressive ; hospital ; anxiety ; depression
hyperkalemia ; wf ; diabetes ; egf ; systolic blood pressure ; hg ; potassium ; hyperkalemia ; study-drug discontinuation ; wf ;hospitalisation ; HF ; cardiovascular mortality
confidence ; baseline glomerular filtration ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; ventricular ejection fraction ; icc ; shocks ; New York Heart association ; atrial fibrillation ; congestive HF ; mortality
oxygen uptake ; hazard ; confidence ; ventilatory efficiency ; hemoglobin ; ventricular ejection fraction ; renal function ; renal disease ; sodium
Kansas City ; Cardiomyopathy ; Questionnaire ; Minnesota ; Living with Heart Failure ; Beck ; depression inventory ; zung ; flow-mediated dilatation diameter ; Fes ; natriuretic peptide ; mitral ; wave
CHF ;Ods ration ; ht ; radiation ; hypertension ; NAD ; h-oxidase ;RAC2 ; hf ; doxorubicin efflux transporter
